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Abstract
Antibiotic resistant bacteria were first reported in the 1940s, several years after the clinical introduction of
penicillin. Since then, antibiotic resistance has contributed to increasing bacterial infections, mortality rates,
and treatment costs. One promising alternative to traditional antibiotics is the development and use of
amphiphiles, compounds with at least one hydrophilic head group and one hydrophobic tail. Three novel
series of triple-headed amphiphiles with variations in the third head group composition, tail length and
number of tails (one or two) were synthesized. Isothermal titration calorimetry was used to determine the
critical micelle concentration – the concentration at which amphiphiles aggregate and form micelles. The
antibacterial activity of individual amphiphiles against six bacterial strains and of binary combinations
against two representative strains was determined by standard antimicrobial microdilution techniques. The
lowest concentration of amphiphile resulting in 50% hemolysis (EC50) was also determined.

For all three amphiphiles series, log of the critical micelle concentration was inversely proportional to tail
length. These series also shared a similar biological trend where antibacterial activity increased with tail
length until an optimal tail length was reached (n = 12 for double-tailed amphiphiles; n = 18 for singletailed amphiphiles). Notably, three compounds (M-P,10,10; M-P,12,12; M-1,12,12) killed multiple
bacterial strains at concentrations ranging from 1-16 µM and were not cytotoxic to blood cells, with EC50
values that were two- to 65-fold higher than bactericidal concentrations. In addition, several combinations
of amphiphiles exhibited synergistic antibacterial activity. These bactericidal, non-hemolytic amphiphiles
could be useful in the medical field, especially when treating or preventing infection with antibiotic
resistant pathogens.
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Chapter 1: Introduction

1.1 Significance
More than two million Americans are infected with antibiotic resistant pathogens each year, resulting in the
death of 23,000 infected individuals. 1 Infection with antibiotic resistant microorganisms can also inflate
treatment costs and prolong the length of hospital stays. 2 One U.S. hospital reported the societal cost of
antimicrobial-resistant infections (ARIs) in a single institution to be $13.35 million per year. The extension
of hospital visits due to ARIs contributes to this cost, with estimates of prolonged hospital stays ranging
from 6-12 days per patient.

2

While reports of mortality rates and increased economic burden due to ARIs have brought attention to this
crisis, antibiotic resistance is not a new phenomenon. Antibiotic resistance was reported as early as the
1940s. Seven years after the introduction of penicillin in 1941, 50% of Staphylococcus aureus isolates were
resistant to this antibiotic. 3 In fact, microorganisms usually acquire resistance to an antibiotic only a few
years after the drug’s clinical introduction. 4,5 This rapid emergence of antibiotic resistance can be attributed
to the mass use of antibacterial agents in healthcare institutes, communities, and the food industry. 6

Hospitals are particularly prone to harboring antibiotic resistant organisms due to the frequent use of
antibacterial agents and influx of infected patients. The frequencies of antibiotic resistance in pathogens
that contributed to hospital-acquired infection (HAI) were estimated in a study performed by the National
Healthcare Safety Network from 2006-2007. In this study, 56% of Staphylococcus aureus isolates were
resistant to oxacillin; 13-19% of Pseudomonas aeruginosa isolates were resistant to extended-spectrum
cephalosporins; and 33% of Enterococcus species were resistant to vancomycin. 7

The presence of antimicrobial resistant pathogens in hospital patients and on equipment threatens modern
clinical practices such as organ transplants, chemotherapy, infant care, and surgery. 1,8 Lack of effective
antimicrobial treatments can lead to the spread of contaminants from equipment, healthcare employees, or
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infected patients to uninfected patients. 9-14 Specific risk factors for HAIs include: stay in a hospital room
previously occupied by an infected patient and contact with contaminated equipment. 9,13,14

The contamination of hospital surfaces and equipment with biofilms is particularly concerning. 15 Biofilms
are difficult to eliminate due to production of the extracellular matrix, which can reduce drug access to cells
in the biofilm. Dormant (non-replicating) cells in the biofilm are also difficult to kill, since most antibiotics
target processes involved in cellular division. Bacteria that express efflux pumps are capable of transporting
antibacterials out of the cytoplasm, allowing for the persistence of cells. Some strains can also produce
enzymes that degrade antibiotics (Fig. 1). 15,16

A common organism that forms biofilms is Pseudomonas aeruginosa, an opportunistic pathogen that is
capable of growing in nutrient-poor conditions and extreme temperatures. 15 P. aeruginosa strains can be
mucoid or non-mucoid. Mucoid strains have a mutation in the negative-regulator mucA gene, which leads
to overproduction of alginate, a capsule-like exopolysaccharide. As a component of the extracellular
matrix, alginate protects P. aeruginosa from inflammatory responses and impedes antibiotic penetration. 17
Nonmucoid P. aeruginosa strains produce little or no alginate but can synthesize alternative
polysaccharides – Ps1 or Pel.
The pel operon is conserved in
all P. aeruginosa strains and
produces a glucose-rich
extracellular matrix. 18,19 The
pel operon is regulated by the
Wsp system, which consists of
eight genes (Fig. 2). WspA is a
chemotaxis receptor that
catalyzes the methylation of
downstream targets, which
ultimately leads to the

	
  

Figure 1. Biofilms are polymicrobial communities with multiple phenotypes.
Production of extracellular polysaccharide (EPS) (green layer) hinders
penetration of antibiotics into the biofilm. Antibacterial resistance strains (blue)
may express drug efflux pumps or enzymes that degrade antibiotics. Dormant
bacteria (orange) are difficult to kill since most antibiotics target machinery
involved in cell division.
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synthesis of cyclic di-GMP and stimulates
biofilm formation. The methylesterase
WspF inhibits cyclic di-GMP formation.
17,20,21

P. aeruginosa strains with mutations

in the wspF gene have upregulated pel
genes and are hyper-biofilm formers. 21,22

P. aeruginosa biofilms have been
identified in hospital water pipes and on
medical devices, such as bronchoscopes,
central venous catheters, and dental
Figure 2. The Wsp system in P. aeruginosa controls the
synthesis of cyclic-di-GMP, which in turn, stimulates EPS
production and other biofilm associated genes. WspF
demethylates downstream targets of WspA and inhibits biofilm
formation.

syringes, and contribute to infection in
patients. 9,15,23 Immunocompromised
patients are especially susceptible to

developing HAIs from biofilm-forming bacteria. P. aeruginosa is commonly found in the lungs of cystic
fibrosis (CF) patients, where approximately 20 percent of CF patients are infected with P. aeruginosa at
less than one year old. 24-26 CF patients have a mutation in the cystic fibrosis transmembrane receptor
(CFTR), resulting in dehydrated surfaces in the lungs and decreased bicarbonate transport across cell
membranes. The decreased secretion of bicarbonate affects the movement of mucus, leading to the
production of dense aggregates of mucus in CF lungs. 25 The thick mucus promotes the colonization of
inhaled bacteria and leads to chronic infection. 27 Bacteria that form biofilms in CF lungs are almost
impossible to treat due to acquired resistance to antibiotics, contributing to a shorter lifespan (40 years) in
patients even though treatment has improved in the past four decades. 24,28

Beginning in 1983, the number of clinically approved antimicrobial agents has steadily dropped,
contributing to growing concern over the treatment of biofilms and antibiotic resistant pathogens. 29 This
rapid decrease in commercially available antimicrobial drugs in the past 30 years is due in part to
deteriorating investment in antibiotic development. 30 Investors have become dissuaded from antibiotic
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development due to short patent life (20 years), unclear regulatory guidelines, time-consuming clinical
testing, and short consumer use of the drug. Instead, the pharmaceutical industry has shifted focus to
chronic diseases, which have longer treatment periods than bacterial infections, and are becoming
increasingly widespread in the U.S. Currently, less than a dozen large pharmaceutical companies focus on
antibiotic development. 4

In the past 15 years, only four novel antimicrobial classes and one new cephalosporin have been approved
for clinical use: Streptogramins (quinupristin and dalfopristin), Oxazolidinones (linezolid), Lipopeptides
(daptomycin), Lipoglycopepides (telavancin), and Ceftaroline. Resistance to these agents has already been
observed in enterococci and staphylococci. 3 Reports of daptomycin-nonsusceptible (DNS) S. aureus and
enterococci are particularly disconcerting as daptomycin is a last-resort drug used to treat multi-drug
resistant (MDR) Gram-positive organisms and is commonly used to treat methicillin-resistant S. aureus
(MRSA) strains that have reduced susceptibility to vancomycin. 3,31

Even fewer antibacterial agents have been recently approved for clinical use against Gram-negative
bacteria. Two new carbapenem antibiotics, ertapenem and doripenem, were introduced in 2001 and 2007,
respectively. 29 Although doripenem has broad-spectrum activity against Gram-positive and Gram-negative
bacteria, reduced susceptibility to doripenem among P. aeruginosa isolates has been reported. 32,33

The presence of antibiotic resistant and biofilm-forming pathogens in a hospital setting is a threat to
medical practices. 1,8,9,11,12,14,34 The development of novel antibacterial compounds is essential in the
sterilization of medical equipment and treatment of bacterial infection caused by antibiotic resistant and
biofilm forming pathogens.

1.2 Amphiphile Background
Amphiphiles, compounds with at least one hydrophobic tail and hydrophilic head group, are a promising
option for antibacterial treatment. While most antibiotics act on specific biological targets within bacteria
such as enzymes involved in transcription, cell wall synthesis, and translation, amphiphiles insert into
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bacterial membranes. Compounds intercalated into the membrane can then disrupt the proton motive force,
interfere with transmembrane proteins, or form openings in the membrane that lead to leakage of ions and
cell death. 35-40 Repair of the cell membrane is a physiologically demanding task for bacteria and could
impede development of resistance. 40

In particular, cationic amphiphiles have promise as antibacterial therapeutics due to the differences in
structure between bacterial and human cell membranes. 41 Bacterial cell membranes contain 20-25%
phosphatidylglycerol and cardiolipin, which are negatively charged phospholipids, resulting in a net
anionic charge (Fig. 3). 41 In contrast, eukaryotic cell membranes are primarily composed of zwitterionic
(neutral) phospholipids, including phosphatidylcholine and phosphatidylethanolamine (Fig. 3). 42 Human
plasma membranes also contain cholesterol, which impedes amphiphilic disruption of the membrane by
increasing mechanical stability of the bilayer. 43,44 These differences in cell membrane structure between
humans and bacteria account for the selectivity of some amphiphiles that disrupt bacterial membranes
while leaving human cell membranes intact.

Low-molecular weight amphiphiles in particular are promising candidates for antibacterial treatment due to
their ability to permeate the outer membrane of Gram-negative bacteria. 36,45 The outer membrane is an
additional lipid bilayer found in Gram-negative organisms that is covalently linked to the peptidoglycan

Figure 3. Comparison of the cell membranes of Gram-positive bacteria, Gram-negative bacteria, and
humans. Gram-positive organisms have a cell wall with a thick peptidoglycan layer. Gram-negative bacteria
also have a peptidoglycan layer, but it is thinner and covered by an additional outer membrane. The outer
membrane contains porins which allow the passage of low molecular weight molecules. The bacterial cell
membrane contains negative phospholipids, resulting in a net anionic charge. In contrast, the human cell
membrane is zwitterionic (neutral) and contains cholesterol, which increases stability of the human cell
membrane.
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layer and consists of anionic lipopolysaccharide, phospholipids, and proteins (Fig. 3). 45 The outer
membrane acts as a barrier to antibiotics and contributes to the intrinsic resistance of Gram-negative
organisms, restricting the size of transportable compounds to less than 700 daltons. 45 Gram-positive
bacteria lack an outer membrane but have a thicker peptidoglycan layer that is relatively open to
extracellular compounds and therefore, does not significantly contribute to antibiotic resistance (Fig. 3). 45

Amphiphiles that demonstrate antibacterial activity against a broad spectrum of microorganisms have been
utilized as antimicrobial agents in detergents, disinfectants, cosmetics, and other common household
products. 46 The use of cationic amphiphiles as an antimicrobial agent was first reported in 1935, when
benzalkonium chloride was used as pre-operative hand soap. 47 Since then, a large variety of novel
amphiphiles have been synthesized in an effort to increase effectiveness and specificity. 35-38,48-63

Amphiphiles make up a broad class of compounds and can differ dramatically in architecture. Conventional
amphiphiles have one tail and one head group. True polycephalic amphiphiles are also single-tailed but
have multiple head groups. 39 Gemini amphiphiles are double-tailed with two head groups attached by a
linker. 63 Bola amphiphiles also contain two head groups but are attached by a longer hydrophobic chain
(Fig. 4). 39 In addition to overall architecture, amphiphiles can vary in length and number of tails;
composition and number of head groups; spacing between head groups; counter ion; and charge. 35-38,48-63
These variations can affect micelle formation and antibacterial activity of amphiphiles.

The effect of structure on critical micelle concentration
Amphiphiles self-assemble into micellar aggregates at the critical micelle concentration (CMC) – exposing
the aqueous head groups to the environment and clustering hydrophobic tails within the micelle. 64 At
concentrations below the CMC, amphiphiles align at the air-water interface in equilibrium with dissolved
monomers (Fig. 5). 64,65 Water molecules form a hydration shell around hydrophobic regions of the
monomers. 66,67 At concentrations above the CMC, amphiphiles form aggregates in which hydrocarbon tails
interact with each other, releasing water that was formerly associated with the tails. This results in a second
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equilibrium between monomers and
aggregates in solution (Fig. 5). 65,68 The
micellization of amphiphiles allows for the
release of water molecules, resulting in a net
increase in entropy of the system. 65,67

Figure 4. Structure of conventional, gemini, bola, and
bicephalic amphiphiles. Amphiphiles contain at least one
hydrophobic tail or linker (gray line) and at least one
hydrophilic head group (black circles).

The CMC is affected by amphiphile
structure. Increasing the length of a tail or
number of tails decreases the solubility of

the compound in aqueous solution and thus decreases the CMC. 61,69 The log(CMC) and tail length have a
linear relationship that follows the equation:
log(CMC) = A – Bn

(1)

where A and B are constants and n is the number of carbons in each hydrocarbon tail. 70,71 The slope of the
line, B, is also affected by the number of hydrophilic units. 72 Increasing the number of head groups
increases the compound’s solubility and CMC. As a result, the CMC of polycephalic amphiphiles has a
weaker dependence (smaller B) on tail length. 50,72 A recent study on dicarboxyl and tricarboxyl
amphiphiles follows this trend. Linear plots of log(CMC) and tail length have a steeper slope for bicephalic
amphiphiles than tricephalic amphiphiles.

50

Studying the relationships between structure and
micellization of amphiphiles can reveal information about
a compound’s mechanism. At concentrations above the
CMC, amphiphiles can act as a detergent in solution,
solubilizing the membrane and forming phospholipiddetergent aggregates.

	
  

49-51,54

Figure 5. As the concentration of amphiphiles
in water reaches the CMC, micelles begin to
form. Figure copied with permission from
Marafino, J. N., "Colloidal and Biological
Properties of Triscationic Amphiphiles with
One or Two Tails" (2014). Masters Theses,
2014 - Paper 7.
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The effect of structure on antibacterial activity
In addition to affecting thermodynamic properties, amphiphile structure also affects antibacterial activity.
The antibacterial activity of a compound is often represented as the minimum inhibitory concentration
(MIC) or minimum bactericidal concentration (MBC), where lower values indicate better antibacterial
activity. Trends relating the head group composition and spacing; number of head groups; charge; and
hydrophobicity to antimicrobial activity have been reported by multiple labs. 37,40,49-51,53-58,62,73

The head group composition of amphiphiles varies and can affect antibacterial properties. When comparing
the effectiveness of pyridinium head groups to that of trimethylammonium head groups in conventional,
bicephalic, and tricephalic amphiphile series, pyridinium compounds have better activity (Table 1). 48 The
pyridinium compounds killed multiple bacterial strains at lower concentrations and in less time than the
trimethylammonium counterparts. 48

In addition to head group composition, the spacing between cationic head groups in polycephalic
amphiphiles can affect antibacterial activity. In a previous study conducted by our research group,
amphiphiles that vary in the number of carbons (4-6) between trimethylammonium head groups were tested
against Gram-negative and Gram-positive organisms. Amphiphiles with a 5-carbon spacer between the
trimethylammoniums had the lowest MIC values. 39

Several labs have reported the trend that antibacterial activity increases with increasing number of cationic
head groups (Table 1). Haldar et al. synthesized two series of amphiphiles consisting of a single tail and
one, two, or three cationic head groups attached to an ester. Both series follow the same trend where
antibacterial activity increases with increasing head groups, with triple-headed amphiphiles having the
greatest antibacterial activity against both Gram-positive and Gram-negative bacteria (Table 1). 48 Similar
results were observed in previous studies by our research group investigating bicephalic and monocationic
(conventional) amphiphiles. Overall, monocationic amphiphiles were ineffective against Gram-negative
organisms whereas bicephalic compounds were more effective against multiple Gram-positive and Gramnegative organisms (Table 1). 39
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Other studies comparing the antibacterial activity of neutral amphiphiles to cationic amphiphiles further
supports the trend that increasing cationic head groups leads to an increase in antibacterial activity (Table
1). The bactericidal activity of quinolium and dipyridinium based compounds were compared to neutral
counterparts. In both series of amphiphiles, the charged compounds had enhanced activity against
planktonic bacteria and biofilms (Table 1). 36,38,40 The presence of a cationic charge likely increases the
antibacterial activity of amphiphiles due to the interaction of cationic head group(s) with the anionic
bacterial cell membrane and Gram-negative outer membrane.

In contrast to the studies previously mentioned, changing the number of dimethylammonium head groups
in novel quaternary ammonium compounds from two to three or four did not significantly affect
antibacterial activity. 58 Similar results were reported for anionic dicarboxyl and tricarboxyl amphiphiles.
The dicarboxyl compounds had better antibacterial activity than their tricarboxyl counterparts, with up to a
50-fold decrease in MIC values.

51

This lack of head group effect on the activity of carboxyl and quaternary

ammonium compounds may be explained by the differences in architecture. The architecture of the
quaternary ammonium compounds are “gemini-like” with hydrophobic linkers between head groups,
forming a chain-like shape. 58 The improved activity of the double-headed versus triple-headed carboxyl
compounds may be explained by the effect of the balance between hydrophobicity and solubility. 51 In order
to have antibacterial activity, a compound must be hydrophilic enough to dissolve in solution and
hydrophobic enough to interact with the nonpolar lipid tails of the bacterial membrane. In this case, the
triple-headed amphiphiles may have been too hydrophilic to interact with the lipid bilayer. 51
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Table 1. Structure-activity trends from studies on novel amphiphiles. *indicates not all
possible combinations of tail lengths synthesized.
Amphiphile(s) Structure

Trend(s)

Reference

!Pyridinium head groups
have better activity than
trimethylammonium
!Increase in # of head
groups led to increased
activity

[48] Haldar, et
al. J. Med.
Chem. 2005,
48, 3823-3831.

!Five carbon spacer has
best activity
!Increase in # of head
groups led to increased
activity
!Moderate tail length has
best activity (12-16
carbons)

[39] Ladow, et
al. Eur. J. Med.
Chem. 2011,
46, 4219-4226.

!Cationic amphiphiles have
better activity than neutral
counterpart
!Moderate tail length has
best activity (12 carbons)

[38] Goswami,
et al. Journal
of Materials
Chemistry B
2013, 1, 26122623.

!Cationic amphiphiles have
better activity than neutral
counterpart
!Moderate tail length has
best activity (12 carbons)

[40] Vudumula,
et al.RSC
Advances.
2012, 2, 38643871.

X+= triethanolamine
R= CnH2n+1
n=14, 16, 18, 20, 22

!Moderate tail length has
best activity (16-20
carbons)

[54] Sugandhi,
et al. J. Med.
Chem. 2007,
50, 1645-1650.

R1= CnH2n+1
n=8, 10, 12, 14, 16, 18*
R2= CmH2m+1
m= 8, 10, 11, 13, 12, 14, 16, 18*

!Moderate tail length has
best activity (22 carbons
total)

[56] Black, et
al. Bioorganic
Med. Chem
Let. 2014, 24,
99-102.

!Moderate tail length has
best activity (22 carbons
total)

[59] Grenier, et
al. Bioorganic
Med. Chem
Let. 2012, 22,
4055-4058

X+ = N+Me3 or pyridinium

n=10, 12, 14,
16, 18

R= CnH2n+1
n=8, 12

R= CnH2n+1
n=8, 12

R1= CnH2n+1
n=1, 2, 4, 6, 8, 10, 11, 12, 14, 16, 18, 20*
R2= CmH2m+1
m=8, 10, 11, 12, 14, 16, 18, 20*

	
  

	
  

11	
  

The hydrophobicity of a compound, determined by the number of polar head groups versus the number and
length of nonpolar tails, influences antibacterial activity by affecting the ability of a compound to
incorporate into the bacterial membrane. Long hydrophobic tails readily incorporate into the nonpolar lipid
bilayer. However, unless balanced by a charged substituent, these compounds are less soluble and can form
aggregates in solution at low concentrations, rendering some amphiphiles useless as antibacterials. 57

Some amphiphiles demonstrate chain length specificity within a particular series, meaning a compound has
an optimal tail length for the greatest antibacterial activity. 35,38-40,53,56,59 Typically, the MIC or MBC of a
compound will decrease with increasing tail length until an optimal length is reached. After this point, the
MIC or MBC increases. The optimal tail length of amphiphiles within a homologous series varies based on
the number of polar head groups and overall architecture. When investigating the effect of tail length on
activity of conventional amphiphiles (one head and one tail), 12 carbon derivatives have the greatest
antibacterial activity against multiple bacterial strains (Table 1). 38,40

Bicephalic amphiphiles follow a similar pattern – the reported optimal tail lengths range from 12-16
carbons, depending on the Gram-nature of the target bacteria (Table 1). 39 Addition of a third head group
extends the optimal tail length to 16-20 carbon tails (Table 1). 49,54 Amphiphiles with non-conventional
architecture are also antibacterial at an optimal tail length. Gemini amphiphiles (double-head, two tails)
have an optimal tail length of 11 or 12 carbons, with a total carbon count of 22-24 carbons (Table 1). 56,59

Relationship between critical micelle concentration and minimum inhibitory concentration
As expected, multiple studies on antibacterial amphiphiles have reported MIC values lower than the CMC.
49-51,54

These results suggest that aggregation is not necessary for amphiphiles to exhibit antibacterial

activity. Rather, these antibacterial amphiphiles likely interact with the bacterial cell membranes as
monomers dissolved in solution. 49-51,54

	
  

	
  

12	
  

Biofilm disrupting amphiphiles
Amphiphiles have potential as novel antibacterial treatment for biofilms. Hospital surfaces and medical
devices contaminated with biofilms are difficult to disinfect and contribute to HAIs. 9,12,15 Biofilms can also
cause bacterial infection in immunocompromised patients, such as in the lungs of CF patients, leading to
chronic infection and inflammation. 24,25 Low molecular weight amphiphiles may be able to penetrate the
extracellular polysaccharide matrix and interact with bacterial cells. 36 Several in vitro studies have
identified amphiphiles that disrupt P. aeruginosa and Gram-positive biofilms. Quinolinium and
dipyridinium amphiphiles eradicated P. aeruginosa and S. aureus biofilms at concentrations ranging from
30-200 µM. 36,62 Novel bisamines and trisamines disrupted S. aureus biofilms at concentrations as low as 50
µM. 73

Synergistic amphiphiles
Some compounds act synergistically when combined with another antibacterial agent. The use of
synergistic combinations of antibiotics has proven beneficial in the treatment of bacteremia, pneumonia,
septic shock, and skin infections. 36,38,62,74-80 Several hospital studies reported that the use of two antibiotics
compared to one contributed to lower mortality rates in patients, including patients infected with antibiotic
resistant pathogens. 76-81 Utilization of combinations of antibiotics has also been reported to help prevent the
emergence of antibiotic resistance in clinical isolates. 82,83

In vitro and in vivo studies demonstrating that cationic amphiphiles act synergistically with antibiotics,
alcohol, and other antimicrobials suggest combination therapy involving the use of amphiphiles has
promise in the treatment of bacterial infection and prevention of the transmission of bacteria. Quinoliniumand dipyridinium-based synthetic amphiphiles interacted synergistically with erythromycin and
tobryamycin against multiple Gram-negative organisms and with polymyxin against S. aureus. 38,62
Furthermore, synergistic combinations of those amphiphiles with tobramycin disrupted in vitro P.
aeruginosa biofilms, with tobramycin concentrations as low as 0.16 µg/ml. 36,62 Electron microscopy
analysis of P. aeruginosa biofilms treated with tobramycin and the dipyridinium compound indicated the
combination disrupted cell-cell adhesion and reduced the amount of extracellular polysaccharide. 36
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Combinations of cationic amphiphiles with another antimicrobial agent have been shown to increase the
efficacy of alcohol hand rubs and soaps. 84-86 One study compared the effectiveness of soaps containing
triclosan, an antibacterial and antifungal agent, to soaps containing a combination of benzethonium chloride
and triclosan. The soap with the combination had better antibacterial activity in a volunteer method and
pig-skin model. In addition, the use of the triclosan-benzethonium chloride combination reduced the risk of
antibiotic resistance development.

85

Early in vitro studies with amphiphiles can identify promising drug leads that are synergistic with other
antibacterial agents, capable of disrupting biofilm, and/or show activity against a broad spectrum of
pathogens. The safety and efficacy of lead compounds must then be determined following the drug
development process.

1.3 Drug Development
The development of drugs follows the same sequence of events and takes 12-15 years of R&D before the
drug is approved by the FDA and can cost up to two billion dollars. 4 The first phase of drug R&D is the
identification of a target for treatment of the disease of interest – usually a protein or specific structure (Fig.
6). An assay must then be developed and used to screen for compounds that are effective at targeting the
structure. 4,87

After identifying drug leads with activity for the target, the specificity and toxicity of the drug candidates
must be investigated (Fig. 6). The cytotoxicity of drugs can be tested in vitro with animal or human cell

Figure 6. Drug development process. The drug development process takes 12-15 years and involves
proving the efficacy and safety of a drug in preclinical and clinical studies.
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cultures. 4,87 Early safety studies on amphiphiles investigated the toxicity with human or sheep red blood
cells and epithelial cell lines. 36-38,40,49,51,62 The concentrations utilized to assess the cytotoxicity of a
compound are EC10 or EC50, the concentration of amphiphile that results in 10% or 50% cell death. The
therapeutic range of an amphiphile can then be calculated by dividing the EC10 or EC50 by the MIC. 3538,49,51,62

Although the therapeutic range is widely used as a measurement of preclinical and clinical toxicity,

no regulations on the analysis of the therapeutic range exist. 88 A larger therapeutic range indicates higher
specificity of an amphiphile for the bacterial target.

After demonstrating the compounds are nontoxic to human cells, the researchers must file an
Investigational New Drug application with the FDA before proceeding with clinical trials. Clinical trials
consist of three (or four) phases (Fig. 6). The first phase tests the compound in a small group of healthy
volunteers to determine if the compound is safe in humans. Phase II involves testing the efficacy of the
drug in diseased individuals and examines short-term effects. The optimal drug dose is also determined in
phase II. Phase III assesses the overall safety and risk-benefit ratio of the drug in a large sample of patients.
After demonstrating the compound is safe in humans and has an acceptable risk-benefit ratio, a New Drug
Application is submitted to the FDA. If the application is approved, the drug can be marketed and made
available for use. In some cases, the FDA may also require a fourth phase study in order to examine longterm safety of the drug. 4,87

1.4 Amphiphiles in the current study
Three novel series of triple-headed amphiphiles were synthesized by the Caran Lab (James Madison
University Department of Chemistry and Biochemistry) and structure-activity relationships were
investigated (Fig. 7). All three series of amphiphiles consist of three cationic head groups attached to a
mesitylene core (M). For the M-P and M-1 series, two of the head groups are dimethylalkylammonium
groups with linear, symmetrical hydrocarbon tails consisting of 8-16 carbons. The third head group is either
pyridinium (M-P) or trimethylammonium (M-1) (Fig. 7a,b) For the M-1,1 series, one of the head groups is
dimethylalkylammonium with a single, linear hydrocarbon tail consisting of 8-22 carbons attached. The
other two head groups are trimethylammonium groups (M-1,1) (Fig. 7c).
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Once synthesized, the effect of amphiphile structure on the colloidal and antibacterial properties was
investigated. The modification of head group composition, number of tails, and length of tail(s), led to the
identification of lead compounds that have antibacterial activity against a broad spectrum of bacteria.
Antibacterial compounds were then tested in combination to identify synergistic combinations, and the
toxicity of antibacterial compounds was determined in hemolysis assays.

a

M-P series
R=CnH2n+1
n=8, 10, 12, 14, 16

b

M-1 series
R=CnH2n+1
n=8, 10, 12, 14, 16

c

M-1,1 series
R=CnH2n+1
n=8, 10, 12, 14, 16, 18, 20, 22

Figure 7. Structure of amphiphiles. (a) M-P series (b) M-1 series (c) M-1,1 series; where M refers to
the Mesitylene core, P represents the pyridinium head group; and n represents the number of
hydrocarbons in the tail; a number indicates the number of carbon atoms in the alkyl group of a
dimethylalkyl ammonium (e.g., 1 = trimethylammonium; 8 = octyldimethylammonium).
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Chapter 2: Colloidal and antibacterial properties of novel triple-headed, double-tailed amphiphiles:
exploring structure-activity relationships and synergistic mixtures

This manuscript has been accepted for publication in Bioorganic & Medicinal Chemistry pending minor
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Abstract:
Two novel series of tris-cationic, tripled-headed, double-tailed amphiphiles were synthesized and the
effects of tail length and head group composition on the critical aggregation concentration (CAC),
thermodynamic parameters, and minimum inhibitory concentration (MIC) against six bacterial strains were
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investigated. Synergistic antibacterial combinations of these amphiphiles were also identified. Amphiphiles
in this study are composed of a benzene core with three benzylic ammonium bromide groups, two of which
have alkyl chains, each 8 to 16 carbons in length. The third head group is a trimethylammonium or
pyridinium. Log of critical aggregation concentration (CAC) and heat of aggregation (∆Hagg) were both
inversely proportional to the length of the linear hydrocarbon chains. Antibacterial activity increases with
tail length until an optimal tail length of 12 carbons per chain, above which, activity decreased. The
derivatives with two 12 carbon chains had the best antibacterial activity, killing all tested strains at
concentrations of 1-2 µM for Gram-positive and 4-16 µM for Gram-negative bacteria. The identity of the
third head group (trimethylammonium or pyridinium) had minimal effect on colloidal and antibacterial
activity. The antibacterial activity of several binary combinations of amphiphiles from this study was
higher than activity of individual amphiphiles, indicating that these combinations are synergistic. These
amphiphiles show promise as novel antibacterial agents that could be used in a variety of applications.

2.1 Introduction
	
  
Over the past few decades, the overuse of antibiotics has resulted in an increase in antibiotic-resistant
bacteria. 89-93 In addition, the production of novel antimicrobials continues to decrease, primarily due to low
financial return. 4,93 This combination of circumstances has contributed to the increasing prevalence of
antimicrobial-resistant infections (ARIs), especially in the hospital setting. ARIs have contributed to tens of
thousands of deaths per year in the European Union and United States alone. 1,94 Hospitals and nursing
homes are particularly prone to harboring antimicrobial-resistant organisms due to the frequent use of
antimicrobial agents and an influx of infected, and frequently, immunocompromised patients. 95 Limiting
the transmission of bacteria from contaminated equipment and individuals to a susceptible population is
critical to reducing the risk of hospital acquired infections by antibiotic resistant organisms. 95,96 The
development of effective novel antibacterials could be of benefit in the healthcare setting by decreasing the
cost associated with treating infected patients, and ultimately, decreasing mortality due to these types of
infections. 97
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The use of cationic amphiphiles as antimicrobials was first reported in 1935. 47 Amphiphiles continue to be
utilized as antimicrobial agents in detergents, disinfectants, cosmetics, and other common household
products. 46 A large variety of novel amphiphiles has been synthesized in an effort to increase effectiveness
and specificity. 39,48,98-106

Amphiphile structure, including size and relative number of hydrophobic tails and hydrophilic head groups,
governs colloidal characteristics including the critical aggregation concentration (CAC) and
thermodynamic properties. 65 At concentrations below the CAC, amphiphiles tend to align at the air-water
interface in equilibrium with dissolved monomers in solution. 65,107 At concentrations above the CAC,
amphiphiles form aggregates in which hydrocarbon tails interact with each other releasing water that was
formerly associated with the tails, resulting in a second equilibrium between monomers and aggregates in
solution. 65,68 An increase in entropy typically associated with aggregate formation is generally attributed in
large part to the release of water molecules surrounding hydrophobic units to the bulk water that
accompanies this process. 65 Increasing amphiphile hydrophobicity (for example by increasing the length or
number of tails) decreases water solubility, thus decreasing CAC. In contrast, additional head groups can
increase amphiphile solubility, typically resulting in a higher CAC. 61,69,108,109

Amphiphile structure also affects antimicrobial effectiveness. A trend reported by multiple studies is the
relationship between amphiphile tail length and the minimum inhibitory concentration (MIC), the lowest
concentration at which an antimicrobial is able to inhibit microbial growth. Typically, as tail length
increases the MIC decreases until an optimal tail length is reached. The MIC then increases for amphiphiles
with tail lengths exceeding this optimal length. 39,98-104 Variations in spacing between head groups can also
impact the MIC. For example, studies conducted by our labs show that amphiphiles with a 5-carbon spacer
between two cationic head groups are the most biologically active. 39 The amphiphiles in the current study
also have a 5-carbon spacer between cationic groups.

Some mixtures of two or more amphiphiles exhibit synergy – the inhibition of bacteria at lower
concentrations than when each amphiphile is used separately. 110 By decreasing the required concentration
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of compounds, combination therapy reduces the potential for, or degree of, adverse side effects and
increases the effectiveness of antibacterial agents. The improved efficacy of synergistic combinations has
contributed to the improvement of hand disinfectants and effective treatment for patients with ARIs.
76,80,85,111

In this report, the synthesis and colloidal, antibacterial, and synergistic characteristics for two novel series
of triple-headed, double-tailed amphiphiles are reported (Fig. 8). Amphiphiles in this study consist of three
cationic head groups connected to a mesitylene (M) core. Two of the head groups are
dimethylalkylammonium groups with linear hydrocarbon tails from 8 to 16 carbons in length. The third
head group is either pyridinium (M-P series) or trimethylammonium (M-1 series).

Figure 8. Structures of triple-headed, double-tailed
amphiphiles in this study. Compounds are named as
follows: M-X,n,n where M refers to the Mesitylene
core, and X and n represent the attached groups: P
indicates a pyridinium; a number indicates the number
of carbon atoms in the alkyl group of a dimethylalkyl
ammonium (e.g., 1 = trimethylammonium; 8 =
octyldimethylammonium).
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2.2 Results & Discussion
Synthesis
Each of the amphiphiles in this study was prepared by two subsequent Menshutkin reactions (Scheme 1).
To prepare the M-P series (1-5), 1,3,5-trisbromomethylbenezene was reacted with a slight excess of
pyridine resulting in intermediate 11 (77% yield). Selective reaction at just one of the three equivalent
benzylic positions was aided by the decreased solubility of the desired product, which precipitates from the
reaction mixture upon formation. Filtration and washing with acetone provides compound 11 in sufficient
purity for the next synthetic step. Substitution of the two remaining benzylic bromides on 11 was
accomplished using excess dimethylalkylamine (NMe2(CH2)n-1CH3, where n = 8, 10, 12, 14 or 16) in
ethanol at reflux producing the M-P series of amphiphilic products 1-5 (63 – 92% yield).

To prepare the M-1 series (6-10), 1,3,5 trisbromomethylbenezene was reacted with a slight excess of
trimethylamine resulting in intermediate 12 (37% yield). This reaction produces primarily 12, along with a
highly insoluble biscationic byproduct (a result of two benzylic bromides being substituted with
trimethylamine), which can be effectively removed by an extraction protocol as detailed in the

Scheme 1. Synthesis of triple-headed, double-tailed amphiphiles.
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experimental section. Substitution of the two remaining benzylic bromides on 12 was accomplished using
excess dimethylalkylamine (NMe2(CH2)n-1CH3, where n = 8, 10, 12, 14, 16) in ethanol at reflux producing
the M-1 series of amphiphilic products 6-10 (20 – 75% yield).

Critical aggregation concentration and heat of aggregate formation
Isothermal titration calorimetry (ITC) was used to determine the critical aggregation concentration (CAC)
and the thermodynamic parameters associated with aggregate formation for each amphiphile (Table 2).
Briefly, the Nano ITC was used
to measure the heat change
associated with the
deaggregation of amphiphiles via
power compensation. 112-115 A
concentrated aqueous solution of
amphiphile (>>CAC) was
titrated into a thermally
controlled sample cell, initially
containing pure water, in a series
of discrete injections. Typical
ITC results can be divided into
three ranges associated with the
Figure 9. Isothermal titration calorimetry was used to determine the
critical aggregation concentration (CAC) and ∆Hagg. a) The heat rate
associated with each injection versus time for 9 (M-1,14,14). b)
Integration of the heat per injection normalized by the number of moles
of each injection versus the increasing concentration of amphiphile in the
well. Inset: CAC is determined by calculating the first derivative the heat
curve.	
  

concentration of amphiphile in
the sample cell below, at, and
above the CAC, as seen for
compound 9 (M-1,14,14, 9).

During initial injections (Range I), measured heat changes are due to both the dilution of aggregates and
deaggregation. This can be observed in the first 10 injections, where aggregates absorbed heat and
disassociated into dissolved monomers.1 The
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Typically the 1st injection is ignored.
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Table 2. Critical aggregation concentration (CAC) and thermodynamic parameters at 37 °C for the M-P and M-1
series.
M-P

M-1

Tail Length
(n for M-X,n,n)

2
3
4
5

7
8
9
10

10,10
12,12
14,14
16,16

CAC (mM)
M-P
14
2.4
0.60
0.18

M-1
12
2.5
0.61
0.16

∆Hagg (kJ/mol)
M-P
-11
-23
-34
-42

M-1
-15
-26
-37
-55

∆Gagg (kJ/mol)
M-P
-21
-26
-29
-33

M-1
-22
-26
-29
-33

-T∆Sagg (kJ/mol)
M-P
-10
-3.1
4.9
9.2

M-1
-6.6
-0.082
8.0
22

heat change produced by each injection was approximately constant in this range. In Range II, injected
aggregates don’t fully dissociate, reducing the total absorbed heat for each subsequent injection. At
concentrations well above the CAC (Range III), absorbed heat is attributed only to the dilution of
aggregates and is approximately constant. The CAC was determined by the inflection point in Range II, as
measured by the minimum value in the plot of CAC versus the first derivative of the heat (Fig. 9, inset).
Analogous results were recorded for compounds 2-5 and 7-10, the results of which are presented in Table
2. CAC and thermodynamic data were not determined for the amphiphiles with the shortest tails [1 (MP,8,8) and 6 (M-1,8,8)] because the heat evolved during injection was above the threshold of the
instrument.

Both series of compounds exhibit a decrease in CAC as tail length increases (Table 2). CAC values for the
M-P and M-1 series are approximately equivalent for each tail length, following a linear plot of log(CAC)
versus tail length (Fig. 10a) according to the equation:

log(CAC) = A – Bn

where A and B are constants and n is the number of carbons in each hydrocarbon tail. 61,70,116 The
dependence of CAC on tail length is the same for each series (B = 0.31).
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1.5

The difference between the average

1.0

heat of injections in Range I,

0.5

representing the total heat due to the

0.0

dilution of aggregates and
deaggregation, and the average heat of

-0.5

injections in Range III, representing the

-1.0
10

12

14

16

heat due solely to the dilution of

∆Hagg (kJ/mol)

-5

aggregates, gives the heat of

-15

deaggregation, ∆Hdeagg. The ∆Hdeagg for

-25

compound 9 (M-1,14,14) is 37 kJ/mol,

-35

corresponding to a heat of aggregate

-45

formation, ∆Hagg, of -37 kJ/mol (∆Hagg

-55
10

12
14
tail length (n for CnH2n+1)

16

Figure 10. Plots of log(CAC) (a) and ∆Hagg (b) versus tail length at
37 °C for the M-P (¢) and M-1 (n) series.

= -∆Hdeagg). The negative ∆Hagg values
indicate that aggregation is an
exothermic process for all of the

amphiphiles in the study (Table 2). This is attributed to the release of heat accompanying aggregate
formation from additional hydrogen bonding of water molecules joining the bulk, and from hydrocarbon
tail interactions in the newly formed aggregate. Furthermore, ∆Hagg becomes more negative as tail length
increases for both series of amphiphiles, following a linear trend (Fig. 10b) according to the equation:

∆Hagg = C – Dn

(2)

where C and D are constants and n is the number of carbons in each hydrocarbon tail. 61,70,116 The
dependence of ∆Hagg on tail length is similar for each series (D = -5.1 for the M-P series; D = -5.8 for the
M-1 series). The inverse relationship between ∆Hagg and amphiphile tail length is consistent with a larger
amount of water released per molecule of amphiphile, as well as greater van der Waals interactions
between the longer tails.
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The ∆Gagg can be approximated for the aggregation of nonionic amphiphiles by the equation

∆Gagg = RT ln (CAC/55.5)

(3)

where the CAC represents an equilibrium between monomeric and aggregated amphiphiles. 71,117 The CAC
is expressed as a molar fraction [molar units divided by the molar concentration of water (55.5 mol/L)].
This equation changes for ionic amphiphiles due to the presence of counterions and the degree of ionization
at the aggregate surface. Thus the equation is modified for an ionic amphiphile as 71,117

∆Gagg = RT [1+(m/n)] ln (CAC/55.5)

(4)

where m is the concentration of counterions that associate with a aggregate and n is the number of
monomers that associate to form an aggregate. 71,117 Since this study did not include determination of the
degree of ionization or aggregate aggregation, ∆Gagg was approximated using equation (3), as has been
done by others. 69,114,115 The ∆Gagg for all compounds in the study is negative and becomes more negative as
tail length increases (Table 2). Thus the increase in chain length within a series of amphiphiles is consistent
with the increased propensity to spontaneously form aggregates.

The entropy of aggregation (∆Sagg) is dictated by a combination of entropic factors that favor or disfavor
aggregate formation and can be approximated using the Gibbs-Helmholtz equation:

∆Gagg = ∆Hagg - T∆Sagg

(5)

To aid the reader, the entropic contribution to ∆Gagg, is presented as the negative of T∆Sagg (Table 2). In
both series, the -T∆Sagg term is negative for amphiphiles with chain lengths of up to 12 carbons [2 (MP,10,10), 3 (M-P,12,12), 7 (M-1,10,10), and 8 (M-1,12,12)]. This suggests that the entropy gained from the
release of water from hydrophobic sections is greater than the decrease in entropy of amphiphiles due to the
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formation of aggregates. Thus the entropic factor, for amphiphiles with shorter chain lengths, contributes to
the spontaneous formation (negative ∆Gagg) of aggregates.

The -T∆Sagg term is positive for double tailed amphiphiles with tail lengths exceeding 12 carbons [4 (MP,14,14), 5 (M-P,16,16), 9 (M-1,14,14), and 10 (M-1,16,16)]. This suggests that the entropy gained from
the release of water from hydrophobic units is smaller than the decrease in entropy of amphiphiles due to
the formation of aggregates. Thus amphiphiles with longer chains entropically disfavor formation of
aggregates making aggregate formation of these derivatives solely an enthalpy-driven process. This
decrease in entropy may be explained by considering the effect of an amphiphile’s cone angle on aggregate
size. 70 As tail length increases in a series of analogous amphiphiles, the cone angle decreases resulting in a
higher aggregation number per aggregate. Formation of larger aggregates results in a larger decrease in
entropy upon aggregate formation due to the greater number of amphiphiles per aggregate.

Minimum inhibitory concentration
The MIC values of all compounds from both series were determined for four Gram-positive
(Staphylococcus aureus, Enterococcus faecalis, Streptococcus agalactiae, and Bacillus cereus) and two
Gram-negative (Escherichia coli and Pseudomonas aeruginosa) strains (Table 3). For both series, the MIC
decreases with tail length until an optimal tail length of 12 carbons per chain, above which the MIC
increases (Fig. 11). The derivatives with two 12-carbon chains, compounds 3 (M-P,12,12) and 8 (M1,12,12), have the lowest MIC values against each strain with values ranging from 1-2 µM for Grampositive bacteria and 4-16 µM for Gram-negative bacteria. This trend is indicative of the relationship
between solubility and bioactivity and is consistent with previous studies on other amphiphile series. 39,98,102
Higher MIC values against Gram-negative strains may be due to their outer membrane, which is not present
in Gram-positive bacteria.

Many antibacterial agents are ineffective against P. aeruginosa due to its semipermeable outer membrane
and production of efflux pumps and β-lactamases. 27 The contamination of medical equipment with P.
aeruginosa biofilms contributes to hospital-acquired infections, particularly caused by antibiotic-resistant
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Table 3. MIC values (µM) for M-P and M-1 amphiphiles. G + = Gram-positive, G - = Gram-negative.
M-P M-1
1
2
3
4
5

6
7
8
9
10

Tail length
(n for M-X,n,n)
8,8
10,10
12,12
14,14
16,16

B. cereus
(G+)
M-P
M-1
>250 >250
8
8
2
2
8
4
>250
16

E. faecalis
(G+)
M-P
M-1
>250 >250
8
8
2
2
4
4
>250
32

S. agalactiae
(G+)
M-P
M-1
>250 >250
8
4
1
2
4
2-4
>250
8

S. aureus
(G+)
M-P
M-1
>250 >250
2
16
2
2
4
4-8
>250
16

E. coli
(G-)
M-P
M-1
>250 >250
16
125
4
4-8
16
8
>250
63

P. aeruginosa
(G-)
M-P
M-1
>250 >250
63
>250
8
16
63
125
>250 >250

strains. 9-12,34 While other antibacterial agents fail to inhibit P. aeruginosa, two amphiphiles in this study [3
(M-P,12,12) and 8 (M-1,12,12)] kill this organism at relatively low concentrations, which may prove useful
in a healthcare setting. Notably, MIC values of compounds 3 (M-P,12,12) and 8 (M-1,12,12) against P.
aeruginosa (8 µM and 16 µM, respectively) are comparable to those of tobramycin (6.4 µM), commonly
used to treat infection in cystic fibrosis patients, and cefepime (12.5 µM), an antispeduomonal
cephalosporin. 118,119

MIC values between respective M-P and M-1 tail lengths were generally similar, indicating that replacing
the trimethylammonium head group with a pyridinium did not significantly affect bioactivity. A notable
exception is observed between the two derivatives with 16-carbon chains, where the trimethylammonium
derivative (10, M-1,16,16) was more effective than the pyridinium derivative (5, M-P,16,16) for all strains
except P. aeruginosa. For all tested compounds, the MBC was the same concentration or a two-fold
concentration higher than the MIC, indicating the amphiphiles are bactericidal, consistent with previous
studies on other multiheaded amphiphiles. 39,120

With only a few exceptions, MIC values are significantly below CAC values, demonstrating that
amphiphile aggregation is not required to kill bacteria. 102 At concentrations near or above the CAC the
amphiphile may act as a detergent, solubilizing the cell membrane – a mechanism of action that could be
detrimental to prokaryotic cells. 100,102 Amphiphiles at sub-CAC levels are potent antibacterials at
concentrations where detergent effects are not observed. It is recognized CAC values reported here
(measured in pure water) may differ to some degree from the CAC values in the medium used for MIC
studies.
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Figure 11. Plot of log(MIC) and tail length for the M-P and M-1 series. (M-P series = ¢; M-1 series =
n). # = MIC > 250 µM. G + = Gram-positive; G- = Gram-negative.

Synergistic combinations
In addition to determining the antibacterial activity of individual amphiphiles, combination studies were
performed in order to determine if binary mixtures of amphiphiles demonstrate synergy in killing
representative Gram-positive (S. aureus) and Gram-negative (E. coli) organisms (Fig. 12). A combination
is considered synergistic if a mixture of amphiphiles has greater antimicrobial activity than simply an
additive effect. The fractional inhibitory concentration (FIC) was used to indicate whether two chemicals
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were synergistic (FIC<0.5), indifferent (FIC 0.5-4.0), or antagonistic (FIC>4.0). 110 Two amphiphile
combinations are synergistic against S. aureus: combinations of compounds 3 and 4 (FIC=0.31) and
compounds 3 and 10 (FIC=0.38). In addition, one combination is synergistic against E. coli: compound 3
and 9 (FIC=0.38). All three synergistic combinations contain compound 3 (M-P,12,12). The use of
synergistic antibacterial combinations could be beneficial in a health-care setting, where frequent
antimicrobial use has contributed to the presence of antibiotic-resistant organisms. 74-76,80,82,85,121

2.3 Conclusions

Two novel series of amphiphiles were synthesized and structure-activity relationships were investigated.
Log (CAC) and ∆Hagg each decrease linearly with increasing tail length for both series. For most of the
amphiphiles in this study, the MIC is significantly below the CAC, indicating amphiphile aggregation is not
necessary for antibacterial activity. MIC values also indicated an optimal tail length of 12 carbons for each
series as compounds 3 and 8 (M-P,12,12 and M-1,12,12) have the lowest MIC against all strains tested.
Furthermore, three binary combinations of amphiphiles have been identified that exhibit synergistic

Figure 12. Synergy studies for M-P and M-1 amphiphiles tested against E. coli
and S. aureus. The FIC value for each combination is given. Shaded blocks
indicate synergistic combinations (FIC <0.5). Numbers below the diagonal
represent FIC values against S. aureus. Numbers above the diagonal represent
FIC values against E. coli.
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relationships. These amphiphiles could prove useful in the medical field especially when treating or
preventing infection with antibiotic-resistant organisms.

2.4 Methods and Materials

Synthesis
Synthesis of 11
1,3,5-tribromomethylbenezene (1.0 g, 2.8 mmol, Sigma-Aldrich) was dissolved in acetone (200 mL) at
room temperature in a round bottom flask. The solution was equipped with a stir-bar and attached to an
addition funnel. Pyridine (0.45 mL, 5.6 mmol, Sigma-Aldrich) was dissolved in acetone (100 mL) and
added drop-wise to the stirring solution of 1,3,5-tribromethylbenzene at room temperature and allowed to
react overnight. A white precipitate formed. The crude reaction mixture was vacuum filtered, washed with
acetone, and dried under vacuum yielding 943 mg (77%) of a tan solid, 11. See Supporting Information for
analytical data.

Synthesis of 12
1,3,5-tribromomethylbenezene (2.01 g, 5.6 mmol) was dissolved in acetone (400 mL) at room temperature
in a round bottom flask. The solution was cooled on an ice bath for 30 minutes, equipped with a stir-bar,
and attached to an addition funnel. An ethanolic trimethylamine solution (1.6 mL, 6.7 mmol, ACROS) was
diluted with acetone (200 mL) and cooled on an ice bath for 30 minutes. The trimethylamine solution was
added drop-wise to the stirring solution of 1,3,5-tribromethylbenzene. The reaction was run overnight, and
allowed to warm slowly to room temperature. A white precipitate containing a mixture of 12 and a
biscationic side product formed. The crude reaction mixture was briefly heated to 50°C and vacuum
filtered. The mother liquor (which contained a mixture of 12 and unreacted starting material) was
transfered to a clean RBF and the solvent was removed by rotary evaporation. The resulting solid was
resuspended in room temperature acetone for 30 minutes, vacuum filtered, and dried under vacuum
yielding 12 (white solid). The solid filtered from the crude reaction mixture was resuspended in a solution
of acetone and ethanol (100:3), heated to 60 °C, stirred for at least 30 minutes, and vacuum filtered. The
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filtrate was transferred to a clean flask and the solvent was removed by rotary evaporation yielding
additional 20 (white solid, total yield = 860 mg, 37%). See Supporting Information for analytical data.

Synthesis of 1-10: General Protocol A
Compound 11 or 12 was added to a two-neck round bottom flask and dissolved in ethanol. The flask was
equipped with a stir bar and attached to a water-cooled condenser. Excess dimethylalkylamine
(NMe2(CH2)n-1CH3,where n = 8, 10, 12, 14 or 16) was added slowly to the flask via syringe. The reaction
was heated to reflux and allowed react overnight. Volatile materials were removed under a flow of N2 (g).
The resulting crude solid was resuspended in acetone to dissolve any residual dimethyalkylamine and
vacuum filtered to yield the solid amphiphile product (1-10). Details for each product and analytical data
are provided in the Supporting Information.
	
  
Isothermal Titration Calorimetry
CAC and ∆Hagg were determined using a Nano-ITC (TA-Instruments). Prior to each experiment the sample
cell was washed with dH2O (300 mL), ethanol (100 mL), dH2O (300 mL) and nanopure water (200 mL).
Next, 950 µL of nanopure water was added to the sample cell. A concentrated aqueous solution (>>CAC)
of amphiphile was prepared and equilibrated at 37 °C. A 250 µL syringe was filled with the aqueous
solution, and loaded into the Nano ITC. Multiple single injections in aliquots of 5 µL were injected into the
sample cell with time intervals varying from 300s to 1400s. Samples were continuously stirred (300 rpm)
throughout the titration. The Nano-Analyze program (TA-Instruments) was used to analyze the data. CAC
and ∆Hagg values reported are the average of two or more repeat experiments for each amphiphile.

Bacterial strains and growth conditions
The Gram-positive bacterial strains used in this study were Staphylococcus aureus subsp.
aureus ATCC® 29213™, Enterococcus faecalis ATCC® 29212™, Bacillus cereus, and Streptococcus
agalactiae J48. 122 The Gram-negative bacterial strains used were Escherichia coli ATCC® 25922™ and
Pseudomonas aeruginosa ATCC® 27853™. All strains were grown in 1X Mueller-Hinton Broth at 37 °C
for 12-24 h. For the MIC and combination studies, bacterial suspensions were prepared by diluting

	
  

	
  

31	
  

overnight cultures to 5 x 106 CFU/mL in 2X Mueller-Hinton Broth (so that when amphiphile solutions are
added, the final broth strength is 1X).

Minimum inhibitory concentration and minimum bactericidal concentration
The methods used to determine the MIC and MBC were performed as previously described and followed
the standards set forth by the Clinical and Laboratory Standards Institute. 39,123 Briefly, compounds were
serially diluted and 100 µL of each dilution were added to the wells of a 96-well flat-bottomed microtiter
plate in triplicate. After adding 100 µL of the bacterial cell suspension, the plates were incubated at 37 °C
for 72 h. The MIC of the compound was defined as the minimum concentration that resulted in visible
inhibition of bacterial growth. In order to determine the MBC, a 100 µl aliquot from each triplicate well
was grown on Todd-Hewitt agar and incubated for 24 h at 37 °C. The MBC was defined as the
concentration of the compound that resulted in a 99.9% reduction of the bacterial CFU/mL. The MIC was
considered to be bactericidal if the MBC was the same concentration or one concentration higher in the
dilution series as the MIC. 120

Combination studies
To determine if two amphiphiles act synergistically to kill E. coli or S. aureus, combination studies were
performed using the checkerboard technique as described. 110 Amphiphiles with MIC values higher than the
maximum concentration used (>250 µM) were excluded from the combination studies. The amphiphile
concentrations used in the combination studies ranged from 1/16 to 2 x the MIC. Fifty microliters of each
amphiphile dilution and 100 µL of the bacterial suspension were added to the wells of a 96-well flatbottomed microtiter plate. Control wells consisted of the bacterial suspension treated with media alone and
bacteria treated with individual amphiphiles. Plates were incubated at 37 °C for 72 h. The FIC index was
calculated using the following formula: FIC = FICA+ FICB = A / MICA + B/MICB. A and B are the MIC
values of compound A and compound B when combined, and MICA and MICB are the MIC of compound
A and B alone. 110 A combination was considered to be synergistic if the FIC was less than 0.5; a
combination was considered indifferent with an FIC of 0.5-4; and a combination was considered
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antagonistic with an FIC > 4. The FIC indices of synergistic combinations were confirmed in two separate
experiments.
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Chapter 3: Antibacterial and colloidal properties of single tailed amphiphiles

3.1 Introduction
The presence of antibacterial resistant pathogens, especially in a hospital setting, calls for the development
of novel antibacterial agents. 1,10,12,124 Compounds that target essential bacterial structures, such as the
bacterial cell membrane and proteins involved in transcription, hinder the development of resistance. 40
Amphiphiles, compounds with at least one hydrophilic head group and hydrophobic tail, are widely
hypothesized to disrupt the bacterial cell membrane and have promise as antibacterials.

35,36,38-40,62

Over the past few decades, a broad spectrum of antibacterial amphiphiles with variations in composition,
number, and spacing of head group(s); number and length of tail(s); and counter ion(s) have been
synthesized. 35-39,48-59,61,62 In a previous study, our research group synthesized novel bicephalic amphiphiles
with modifications in tail length (12-18 carbons) and spacing between head groups attached to an aromatic
ring (4-6 carbons). 39 Structure-activity studies demonstrated bicephalic compounds with tail lengths of 1214 carbons and 14-16 carbons are the most effective against Gram-positive and Gram-negative organisms,
respectively. In addition, the amphiphiles with a 5-carbon spacer between head groups (2,4- or 3,5substitution pattern around an aromatic ring) have better antibacterial activity than homologues with a 4- or
6-carbon spacer. 39 Because of this, subsequent series of novel compounds synthesized by our research
group have incorporated a 5-carbon spacer between head groups.

A recent study conducted by our research group investigated the structure-activity trends of two series of
triple-headed, double tailed amphiphiles with a 5-carbon spacer between head groups around an aromatic
core (1,3,5- substitution pattern) with tail lengths ranging from 8-16 carbons. (Table 4). 60 The antibacterial
activity of both series is affected by tail length, where the compounds with tail lengths of 12 carbons are the
most effective (Table 4). 60 Compounds with tail lengths of less than or more than 12 carbons have
decreased activity.

	
  

Single tailed

	
  

Double tailed

10,
11,
12,
13,
14,

B1,
B2,
B3,
B4,
B5,

R=C14H29
R=C16H33
R=C18H37
R=C20H41
R=C22H45

R=C8H17 (M-P,8,8)
R=C10H21 (M-P,10,10)
R=C12H25 (M-P,12,12)
R=C14H29 (M-P,14,14)
R=C16H33 (M-P,16,16)

X+

N+Me3

1, R=C8H17 (M-1,1,8)
2, R=C10H21 (M-1,1,10)
3, R=C12H25 (M-1,1,12)
4, R=C14H29 (M-1,1,14)
5, R=C16H33 (M-1,1,16)
6, R=C18H37 (M-1,1,18)
7, R=C20H41 (M-1,1,20)
8, R=C22H45 (M-1,1,22)

15,
16,
17,
18,
19,

B11,
B12,
B13,
B14,
B15,

R=NHC14H29
R=NHC16H33
R=NHC18H37
R=NHC20H41
R=NHC22H45

B6, R=OC14H29
B7, R=OC16H33
B8, R=C18H37
B9, R=OC20H41
B10, R=OC22H45

A1, R=C14H29 ,
=
A2, R=C14H29 , X+ = Pyridinium

R=C8H17 (M-1,8,8)
R=C10H21 (M-1,10,10)
R=C12H25 (M-1,12,12)
R=C14H29 (M-1,14,14)
R=C16H33 (M-1,16,16)

Amphiphile Series

B14 [20]

230-320

1400

NA

B9 [20]

7.7-92

9.4-48

7.8-83

3.5-6.5

9-11.3

2-16

2

1-2

120

64-250

120-480

NA

4.9-5.2

7.3-9.6

16-125

8-16

4-8

Reference

[47] Haldar et al.
2005. J. Med.
Chem.

Current study

[56] Williams et al.
High density inoculum,
2007. J. Antmicrob.
(108 CFU/mL) including E.
Chem.
faecalis, S. aureus, E. coli,
and Klebsiella pneumoniae.

Broth microdilution.

[50] Maisuria et al.
Low density inoculum
2011. Bioorganic &
(105 CFU/mL), with S.
Med. Chem.
aureus strains (including
MRSA).

Broth microdilution.

High density inoculum
(107 – 109 CFU/mL), with
tested organisms: E.
faecalis, S. aureus, E. coli,
Shigellas sonnei

Spread-plate method
(MBC).

Moderate density inoculum
(5 x 106 CFU/mL), with
E. faecalis, S. aureus,
P. aeruginosa, E.coli.

Broth microdilution.

Broth microdilution &
spread-plate method (MBC).
[59] Marafino et al.
Moderate density inoculum 2015. Bioorganic &
Med. Chem.
(5 x 106 CFU/mL), with E.
faecalis, S. aureus,
P. aeruginosa, E.coli.

Method

Antibacterial Activity
MIC [µM] MIC [µM]
(G+)
(G-)

120-670

0.3*

B14 [20]

Pyrene
flourescence.
Dissolved in
aqueous
treithanolamine
(0.9 w/v)
25%° C

NA

Isothermal
titration
calorimetry.
Dissolved in
water 37° C

Isothermal
Titration
calorimetry.
Dissolved in
water 37° C

Method for
determining
CAC

B5 [22]

0.3*

0.4*

5

2.5

2.4

B9 [20]

B5 [22]

A2 [14]

A1 [14]

6 [18]

17 [12,12]

12 [12,12]

Representative
Compound
[Length of tail(s)] CAC (mmol/L)

Colloidal Properties

Table 4. Comparison of antibacterial and colloidal properties of triple-headed amphiphiles. Representative compounds that have broad antibacterial activity were selected for
comparison of critical aggregate concentration (CAC) and minimum inhibitory concentration (MIC). The provided MIC values are ranges for representative organisms listed for
each method. G+ = Gram-positive; G- = Gram-negative; MBC = minimum bactericidal concentration; NA = Not available. *indicates values estimated from log(CAC) plots
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Amphiphiles with tail-length specificity typically follow this trend, where MIC decreases as tail length
increases until an optimal tail length is reached. After this point, the MIC begins to increase with increasing
tail length. 39,51,54,59,60 One study investigated the effect of tail length on three series of triple-headed, single
tailed amphiphiles with modifications in linker composition (B1-B15, Table 4). These three series of
amphiphiles have an optimal tail length of 20 or 22 carbons (Table 4). 51,57 For the two series with an
optimal tail length of 20 carbons, the tail length trend was evident – the MIC values increase for
compounds containing more or less than 20 carbons (Table 4). 51,57

Amphiphile structure also affects the critical aggregation concentration (CAC). Plots of log(CAC) and tail
length show a linear relationship, where the slope of the line is affected by amphiphile structure. The CAC
values of triple-headed, single tailed amphiphiles have a modest dependence on tail length (Fig. 13). 51,125
In comparison, single- and double-headed amphiphiles typically have CAC values with a greater
dependence on tail length (steeper slope). 72

The relationship between the CAC and the MIC can reveal information about the mechanism of action of
an amphiphile. Multiple studies reported MIC values of amphiphiles that were below the CAC values
(Table 4). 49-51,54,60A compound with a MIC below the CAC does not require aggregation to inhibit bacteria,
likely eliminating detergent-driven lysis as a possible mechanism. 49-51,57

In order to further investigate the effect of structure on colloidal and antibacterial properties of tripleheaded amphiphiles, novel single tailed amphiphiles were synthesized. The triple-headed, single tailed
amphiphiles contain two trimethylammonium head groups (M-1,1, series) and one
alkyldimethylammonium head group attached to one tail ranging in length from 8-22 carbons (1-8) (Fig.
13). Some of these amphiphiles were bactericidal against a broad spectrum of Gram-positive and Gramnegative bacteria and are potential drug candidates for further antibacterial and toxicity studies.
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1, R=C8H17 (M-1,1,8)
2, R=C10H21 (M-1,1,10)
3, R=C12H25 (M-1,1,12)
4, R=C14H29 (M-1,1,14)
5, R=C16H33 (M-1,1,16)
6, R=C18H37 (M-1,1,18)
7, R=C20H41 (M-1,1,20)
8, R=C22H45 (M-1,1,22)
Figure 13. Structure of M-1,1,n amphiphiles. Amphiphiles are named as follows: M-n,n,n
where M refers to the Mesitylene core, and n represents the number of hydrocarbons in the
tail; a number indicates the number of carbon atoms in the alkyl group of a dimethylalkyl
ammonium (e.g., 1 = trimethylammonium; 8 = octyldimethylammonium).

3.2 Results and Discussion
Synthesis2
Each of the amphiphiles in this study was prepared by two subsequent Menshutkin reactions (Scheme 2).
To prepare the M-1,1 (1-8) series, 1,3,5 trisbromomethylbenezene was reacted with two equivalents of
trimethylamine resulting in intermediate 9. Selective reaction at just two of the three equivalent benzylic
positions was aided by the decreased solubility of the desired products, which precipitate from the reaction
mixture upon formation. Filtration of the reaction mixture followed by subsequent washes with a solution
of acetone and ethanol yields intermediate 9. Substitution of the remaining benzylic bromide on 9 was
accomplished using a slight excess of dimethylalkylamine (NMe2(CH2)n-1CH3, where n = 8, 10, 12, 14, 16,
18, 20, or 22) in ethanol at reflux producing the series of amphiphilic products 1-8.

Br

N
NMe 3 (2 eq)

N
2 Br

Br

3 Br

EtOH
reflux

Acetone/EtOH
0o C
RT
Br

NMe2 R

Br

N
9

N
R

N
1 -8

Scheme 2. Synthesis of triple-headed, single-tailed amphiphiles.

	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
2	
  Section modified from Marafino, J. N. "Colloidal and Biological Properties of Triscationic Amphiphiles
with One or Two Tails" (2014). Masters Theses, 2014 - Paper 7.
http://commons.lib.jmu.edu/master201019/7	
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Critical aggregation concentration
The M-1,1, series exhibit a decrease in CAC as tail length increases, where a linear plot of log(CAC) versus
tail length follows the equation:
log(CAC) = A – Bn

(1)

where A and B are constants and n is the number of carbons in each hydrocarbon tail (Table 5, Fig. 14).
61,70,116

The plot of log(CAC) versus tail length indicates moderate dependence of CAC on tail length

(B=0.16) and is consistent with other reports on triple-headed, single tailed amphiphiles. 51,125
Table	
  5.	
  CAC,	
  ∆Hagg,	
  ∆Gagg,	
  and	
  -‐T∆Sagg	
  for	
  the	
  M-‐1,1	
  series.	
  Experiments	
  were	
  performed	
  at	
  37°C.	
  
	
  
M-1,1
Tail Length
CAC [mM]
∆Hmic (kJ/mol)
∆Gmic (kJ/mol)
-T∆Smic (kJ/mol)
Compound (#)
(n for M-1,1,n)

4

14

21

-10

-20

-10

5

16

11

-12

-22

-10

6

18

5.0

-22

-24

-2.4

7

20

2.0

-28

-26

1.6

8

22

0.99

-33

-28

5.1

log [CAC (mmol/L)]

1.5
y = -0.1686x + 3.7068
1.0

Antibacterial activity
The MIC values of 1-8 were determined for

0.5

four Gram-positive strains (Bacillus cereus,

0.0

Enterococcus faecalis, Staphylococcus

-0.5
12

14
16
18
20
tail length (n for CnH2n+1)

22

24

Figure 14. Plot of log(CAC) versus tail length for the M-1,1
series. The slope of the line is given.
Table 5. CAC, ∆Hmic, ∆Gmic, and T∆Smic for the M-1,1 series.

aureus, Streptococcus agalactiae) and two
Gram-negative strains (Escherichia coli,
Pseudomonas aeruginosa) (Table 6, Fig.

15). For the M-1,1 series, compound 6 (M-1,1,18) has the lowest MICs (2-125 µM) for all tested strains
(Table 6, Fig. 15). The MIC values of 6 (M-1,1,18) are lowest for S. agalactiae (2 µM) and highest for P.
aeruginosa (125 µM). Reduced activity against Gram-negative strains is likely due to the presence of an
additional outer membrane, which hinders the passage of extracellular molecules. P. aeruginosa especially
is difficult to kill due to expression of selective porins and overproduction of drug efflux pumps. 27
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Table 6. MIC values (µM) of amphiphiles from the M-1,1,n and M-1,n,n series, where n represents the number of
carbon atoms in the alkyl group of a dimethylalkyl ammonium. *The MIC values of M-1 series were determined in
a previous study and were included for comparison.

M-1,n,n*

M-1,1,n

Compound

Tail length
B. cereus (G+)
(n for CnH2n+1)

1
2
3
4
5
6
7
8
10
11
12
13
14

8
10
12
14
16
18
20
22
8
10
12
14
16

>250
125
63
16
4
4
4
>250
>250
8
2
4
16

60

+

-

G = Gram-positive; G = Gram-negative.

E. faecalis (G+)

S. agalactiae (G+)

S. aureus (G+)

E. coli (G-)

P. aeruginosa (G-)

>250
250
250
31
8
4
4
>250
>250
8
2
4
32

>250
125
125
16
4
2
4
>250
>250
4
2
2
8

>250
>250
63
63
31
16
16
>250
>250
16
2
8
16

>250
>250
>250
250
31
16
31
63
>250
125
4
8
63

>250
>250
>250
>250
>250
125
250
>250
>250
250
16
125
>250

Compounds 5 (M-1,1,16) and 7 (M-1,1,20) have similar activity to 6 (M-1,1,18), varying in MIC values for
the majority of organisms by a two-fold difference at most (Table 6).

In addition to determining the MIC values for all compounds, the minimum bactericidal concentration
(MBC) values were determined for compounds with low MICs (4-7) by the spread-plate method. The
MBCs of compounds 4-7 were equivalent to MIC values, indicating these compounds kill bacteria at low
concentrations.

The antibacterial activity of the M-1,1 series is dependent on tail length, as demonstrated by the trend that
the MICs decrease with increasing tail length until an optimal tail length is reached (Table 6, Fig. 15). The
optimal tail lengths for three of the Gram-positive organisms are 18- and 20- carbons (compounds 6, 7),
which have equivalent MIC values (Table 6, Fig. 15). The 18-carbon tailed compound (6) had the lowest
MIC values for S. agalactiae and the two Gram-negative organisms (Table 6, Fig. 15). The MIC values of
the longer tailed compound (8) increase for all tested organisms. This phenomenon is widely reported and
is most likely explained by a balance between the solubility and hydrophobicity of the compound. 3840,50,51,54,57,59

Amphiphiles with longer tails are more effective at interacting with the hydrophobic

phospholipid bilayer in the bacterial cell membrane. However, compounds with low solubility can form
aggregates in solution and have decreased efficacy against bacteria. 50,51
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MIC (µM)

#

B. cereus (G+)

#

250

250

200

200

150

150

100

100

50

50

0

#

MIC (µM)
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S. aureus (G+)
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#
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8

E. coli (G-)
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100
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50
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0
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P. aeruginosa (G-)
# #
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#

0
8

10 12 14 16 18 20 22
Tail length (n for CnH2n+1 )

8

10 12 14 16 18 20 22
Tail length (n for CnH2n+1 )
+

Figure 15. Effect of tail length on the MIC for the M-1,1 series. # = MIC > 250 µM. G =
Gram-positive; G = Gram-negative.
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Comparison of colloidal and antibacterial properties of single tailed and double tailed amphiphiles
In order to determine the effect of number of tails on CAC and MIC, results from a previous study on
triple-headed, double tailed amphiphiles analogous in structure to the single tailed M-1,1 compounds were
compared to the results from the current study (Tables 3.1-3.4). 60 Overall, the double tailed compounds
have lower MIC and lower CAC values, when compared to the single tailed counterparts. In addition, the
CAC values of the double tailed amphiphiles have a greater dependence on tail length (Table 7).

The most effective compound from the double-tailed M-1 series [12 (M-1,12,12)] has a two to eightfold
decrease in MICs against the majority of organisms compared to the MICs of compound 6 (M-1,1,18)
(Table 6). 60 The double-tailed compound 12 (M-1,12,12) also has a lower CAC than the single-tailed
compound 6 (M-1,1,18), indicating 12 is less soluble (Table 7). When comparing the MIC and CAC values
of double and single tailed amphiphiles with equivalent tail length (e.g. M-1,1,14 and M-1,14,14), the
double tailed amphiphiles have better overall antibacterial activity and lower solubility (lower CAC)
(Tables 6,7).

When comparing the total number of carbons in the tail(s) (e.g. M-1,8,8 and M-1,1,16), the double tailed
compounds have higher CAC values than single tailed analogues (Table 7). The distribution of
hydrocarbon groups across two tails increases the solubility of compounds, resulting in a higher CAC for
double tailed amphiphiles.

Antibacterial trends concerning the effect of total number of carbons in the tail(s) are not as apparent.
When examining compounds with 16 carbons total in the tail(s), single tailed compound 5 (M-1,1,16) is
much more effective than double tailed 10 (M-1,8,8) (Tables 6,7). In contrast, the antibacterial activity of
the compounds with 20 total carbons in the tail(s) [7 (M-1,1,20) and 11 (M-1,10,10)] is approximately
equivalent (Tables 6,7). Since the tail length did not exceed 22 carbons for the M-1,1 series, the efficacy of
analogues with more than 22 carbons total in the tail(s) were not compared. However, comparisons of the
two sets of compounds with equal number of carbons in the tail(s) (16 total carbons) indicate single tailed
compounds with moderate tail length (M-1,1,16) are more effective than double tailed analogues with short
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tails (M-1,8,8). When the tail length(s) of both single tailed and double tailed compounds were relatively
moderate in length (10 carbons for double tailed and 20 carbons for single tailed), the antibacterial
activities were nearly equivalent (Tables 6,7).

Comparison of these two series indicates antibacterial and colloidal properties are affected by both length
of tail and number of tail(s). The number of tails affects the geometry of amphiphiles, which may also
explain differences in activity of the single tailed and double tailed amphiphiles. Triple-headed, one tailed
amphiphiles have a cone shape, whereas double tailed amphiphiles have more of a cylindrical shape.
Phospholipids are cylindrical as well, which may explain the enhanced activity of the double tailed
amphiphiles. 126 This similarity in geometry may contribute to the insertion of double tailed amphiphiles
into the phospholipid bilayer.

Table 7. Comparison of CAC (mM) and MIC values (µM) of amphiphiles that vary in number of tails.
The M-1,1,n series is single tailed, and the M-1,n,n series is double tailed, where n represents the number
of carbons in each alkyl group attached to a dimethlylalkyl ammonium. The CAC and MIC values of the
59 +
M-1,n,n series were determined in a previous study and included for comparison. G = Gram-positive;
-

G = Gram-negative. *The CAC of M-1,8,8 was not determined but can be estimated to be approximately
46 mM based extrapolation of data from the other amphiphiles in this series.

Most effective
amphiphiles
from each series
Comparison of
amphiphiles
with equal #
carbons per
tail(s)

Comparison of
amphiphiles
with equal #
total carbons in
tail(s)

	
  

Compound #

Tail Length
(n,n for M-1,n,n
or n for M-1,1,n)

Total # carbons
in tail(s)

CAC (mM)

12

12,12

24

6

18

13

Range of MIC values (µM)
!

(G+)

(G-)

2.5

2

4-16

18

5

2-16

16-125

14, 14

28

0.61

2-8

8-125

4

14

14

21

16-63

250->250

14

16,16

32

0.16

8-31

63->250

5

16

16

11

4-31

31->250

10

8,8

16

≈46

>250

>250

5

16

16

11

4-31

31->250

11

10,10

20

12

4-16

125-250

7

20

20

2

4-16

31-250
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Combination Studies
A previous study on the two series of triple-headed, double tailed amphiphiles identified three synergistic
combinations consisting of two compounds from one or both series. 60 To determine if single tailed and
double tailed amphiphiles are synergistic, studies of binary combinations were performed with E. coli and
S. aureus. The fractional inhibitory concentration (FIC) was used to assess the interactions between two
compounds. A combination was considered to be synergistic if the FIC<0.5, or if the MICs of each
amphiphiles decreased more than fourfold. 110 Theoretically, a twofold decrease in the MIC would be
considered a synergistic combination. However, a more conservative threshold of FIC<0.5 is widely used
to allow for a one well dilution error in the assay. 127 None of the combinations involving at least one M-1,1
compound have FICs<0.5 (Fig. S1). However, several combinations had FIC values <1.0, suggesting these
combinations could be considered synergistic. The broad-spectrum efficacy of these compounds could be
useful in a clinical setting potentially for the treatment of bacterial infection, disinfection of contaminated
equipment, or prevention of bacterial colonization on hospital surfaces.

3.3 Conclusions
The effect of amphiphile structure on colloidal and antibacterial characteristics was investigated for a novel
series of triple-headed, single tailed amphiphiles. A linear plot of log(CAC) and tail length indicates the
CAC of the M-1,1 amphiphiles is moderately dependent on tail length. The antibacterial activity of these
compounds is also dependent on tail length as indicated by the low MIC values of the 18 and 20 carbon
tailed derivatives (6, 7). The MIC values of compound 6 were in the single digit micromolar range for three
Gram-positive organisms and ranged from 16-125 µM for S. aureus, E. coli, and P. aeruginosa.
Comparison of these single tailed compounds to double tailed compounds from a previous study indicated
colloidal and antibacterial activity is affected by the number and length of tail(s). The broad spectrum
efficacy of these compounds could be useful for the treatment of bacterial infection or sterilization of
contaminated medical equipment.
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3.4 Methods & Materials

Synthesis
Synthesis of intermediate 93
1,3,5-tribromomethylbenezene (1.0 g, 2.8 mmol) was dissolved in acetone at room temperature in a round
bottom flask (RBF). The solution was cooled on an ice bath for 30 minutes, equipped with a stir-bar, and
attached to an addition funnel. An ethanolic trimethylamine solution (1.2 mL, 5.6 mmol) was dissolved in
acetone and cooled on an ice bath for 30 minutes. The trimethylamine solution was added drop-wise to the
stirring solution of 1,3,5-tribromethylbenzene. The reaction was run overnight, and warmed slowly to room
temperature. A white precipitate containing a mixture of 9 (M-1,1) and side product formed. The crude
reaction mixture was vacuum filtered and resuspended in a solution of acetone and ethanol (100:3), heated
to 60°C, stirred for at least 30 minutes, vacuum filtered, and dried under vacuum to produce 9 (M-1,1)
(856.4 mg, 64.05%, white solid).

Synthesis of 1-8: General Protocol A3
9(M-1,1) was added to a two neck round bottom flask and dissolved in ethanol. The flask was equipped
with a stir bar and attached to a water-cooled condenser. Alkyl amine (NMe2(CH2)n-1CH3,where n = 8, 10,
12, 14, 16, 18, 20, or 22) was added slowly to the flask using a syringe. The reaction was heated to 80°C
and run overnight at reflux. Volatile materials were removed under a flow of N2 (g). The resulting crude
solid was resuspended in acetone, vacuum filtered, and dried in under vacuum to yield the solid amphiphile
product (1-8).

Isothermal Titration Calorimetry3
CAC and ∆Hmic were determined using a Nano-ITC (TA-Instruments). Prior to each experiment, the sample
cell was washed with dH2O (300 mL), ethanol (100 mL), dH2O (300 mL) and nanopure water (200 mL).
Next, 950 µL of nanopure water was added to the sample cell. A concentrated aqueous solution (>>CAC)

	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
3	
  Sections modified from Marafino, J. N. "Colloidal and Biological Properties of Triscationic Amphiphiles
with One or Two Tails" (2014). Masters Theses, 2014 - Paper 7.
http://commons.lib.jmu.edu/master201019/7	
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of amphiphile was prepared and equilibrated at 37°C. A 250 µL syringe was filled with the aqueous
solution, and loaded into the Nano ITC. Multiple single injections in aliquots of 5 µL were injected into the
sample cell with time intervals varying from 300s to 1400s. Samples were continuously stirred (300 rpm)
throughout the titration. The Nano-Analyze program (TA-Instruments) was used to analyze the data. CAC
and ∆Haggregate values reported are the average of two or more repeat experiments for each amphiphile.

Bacterial strains and growth conditions
The Gram-positive bacterial strains used in this study were Staphylococcus aureus subsp.
aureus ATCC® 29213™, Enterococcus faecalis ATCC® 29212™, Bacillus cereus, and Streptococcus
agalactiae J48. 122 The Gram-negative bacterial strains used were Escherichia coli ATCC® 25922™ and
Pseudomonas aeruginosa ATCC® 27853™. All strains were grown in 1X Mueller-Hinton Broth at 37 °C
for 12-24 h. For the MIC and combination studies, bacterial suspensions were prepared by diluting
overnight cultures in 2X Mueller-Hinton Broth to 5 x 106 CFU/mL.

Minimum inhibitory concentration and minimum bactericidal concentration
The methods used to determine the MIC and MBC were performed as previously described and followed
the standards set forth by the Clinical and Laboratory Standards Institute. 39,123 Briefly, compounds were
serially diluted and 100 µL of each dilution were added to the wells of a 96-well flat-bottomed microtiter
plate in triplicate. After adding 100 µL of the bacterial cell suspension (5 x 106 CFU/mL), the plates were
incubated at 37 °C for 72 h. The MIC of the compound was defined as the minimum concentration that
resulted in visible inhibition of bacterial growth.

The MBC was determined for compounds 4-6. In order to determine the MBC, a 100 µl aliquot from each
triplicate well was grown on Todd-Hewitt agar and incubated for 24 h at 37 °C. The MBC was defined as
the concentration of the compound that resulted in a 99.9% reduction of the bacterial CFU/mL. The MIC
was considered to be bactericidal if the MBC was the same concentration or one concentration higher in the
dilution series as the MIC. 120
Combination studies
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To determine if two amphiphiles act synergistically to kill E. coli or S. aureus, combination studies were
performed using the checkerboard technique previously described. 60 Binary combinations consisted of M1,1 compounds combined with another single tailed compounds or double tailed compounds from a previus
study. 60Amphiphiles with MIC values higher than the maximum concentration used (>250 µM) were
excluded from the combination studies. The amphiphile concentrations used in the combination studies
ranged from 1/16 to 2 x the MIC. Fifty microliters of each amphiphile dilution and 100 µL of the bacterial
suspension were added to the wells of a 96-well flat-bottomed microtiter plate. Control wells consisted of
the bacterial suspension treated with media alone and bacteria treated with individual amphiphiles. Plates
were incubated at 37 °C for 72 h. The FIC index was calculated using the following formula: FIC = FICA+
FICB = A / MICA + B/MICB. A and B are the MIC values of compound A and compound B when
combined, and MICA and MICB are the MIC of compound A and B alone. 110 A combination was
considered to be synergistic if the FIC was less than 0.5; a combination was considered indifferent with an
FIC of 0.5-4; and a combination was considered antagonistic with an FIC > 4. The FIC indices of
synergistic combinations were confirmed in two separate experiments.
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Chapter 4: Cytotoxicity studies on amphiphiles
4.1 Introduction
Drug development is a tedious task, often taking 12-15 years of research and development and costing 800
million to two billion dollars. 4 The development process involves identifying effective compounds in in
vitro or in silico studies, testing the safety of drug candidates in preclinical safety studies using in vitro cell
culture and animal models, and then moving forward to clinical studies.

4,88

In preclinical and clinical

safety studies, the therapeutic index (TI) is used to compare the effectiveness of a compound to its toxicity.
The TI is the concentration of drug that is considered to be safe with a particular model divided by the
concentration of drug required to inhibit the target of interest. A larger TI indicates the drug candidate is
more selective for the target and presumably, safer. 4,88 Although the TI is widely used in toxicity studies,
no universal regulations concerning the interpretation of the TI exist. It is impossible to define a universal
standard for the TI, because it will vary based on the phase of the study, model used, and properties of the
drug candidate. Typically, the TI is interpreted in a case-by-case basis by experts who assess the drug’s
safety after thorough investigation of the drug during and after multiple preclinical studies and clinical
studies. 88 Clinical studies must demonstrate the compound is safe and effective before the drug is approved
by the FDA and available for prescription. 4

Early safety studies on antibacterial amphiphiles utilize eukaryotic cell lines or red blood cells (RBCs) to
identify potential leads that are both safe and effective. 36-38,49,51 The hemocomptability (safety to RBCs) of
drug candidates can be investigated in in vitro hemolysis studies and can identify potential drug leads.
Understanding a compound’s interaction with blood cells is necessary before administering the drug to
humans. Even if a compound’s intended use does not involve intravenous injection, a drug may still be
absorbed into the blood stream after oral or aerosol administration. 128

In toxicity studies, sheep blood is often used as model for human blood because of similarities in red blood
cell production and development. 129 The TI for hemolysis studies is computed by dividing the effective
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concentration that results in 50% hemolysis (EC50) or 10% hemolysis (EC10) by the compound’s minimum
inhibitory concentration (MIC). 37,49,51 Although hemolysis assays are a cost-effective and simple
method to identify potential drug leads, the assay is limited by the fragility of the red blood cells. Proper
storage and processing of red blood cells is essential to ensure cell viability and avoid hemolysis caused by
mechanical or temperature stress. 130 In addition, the presence of nonaqueous cosolvents in the blood can
affect the spectrophotometer readings, so red blood cells should be studied in pure aqueous solvent, further
increasing their susceptibility to hemolysis. 131 Still, if the blood cells are maintained properly, hemolysis
studies can be used to identify potential non-toxic drug leads.

This study investigated the cytotoxicity of three novel series of amphiphiles that were antibacterial against
a broad spectrum of pathogens. 60 All three series of amphiphiles consist of three cationic head groups
attached to a mesitylene core (M). For the M-P and M-1 series, two of the head groups are
dimethylalkylammonium groups with hydrocarbon tails consisting of 8-16 carbons. The third head group is
either pyridinium (M-P) (Fig. 16c) or trimethylammonium (M-1) (Fig. 16b). For the M-1,1 series, one of
the head groups is dimethylalkylammonium with a single, linear hydrocarbon tail consisting of 8-22
carbons attached. The other two head groups are trimethylammonium groups (M-1,1) (Fig. 16a).

a

c

b

1, R=C8H17 (M-1,1,8)
2, R=C10H21 (M-1,1,10)
3, R=C12H25 (M-1,1,12)
4, R=C14H29 (M-1,1,14)
5, R=C16H33 (M-1,1,16)
6, R=C18H37 (M-1,1,18)
7, R=C20H41 (M-1,1,20)
8, R=C22H45 (M-1,1,22)

10,
11,
12,
13,
14,

R=C8H17 (M-1,8,8)
R=C10H21 (M-1,10,10)
R=C12H25 (M-1,12,12)
R=C14H29 (M-1,14,14)
R=C16H33 (M-1,16,16)

Figure 16. Structure of (a) M-1,1 (b) M-1 and (c) M-P series.

	
  

15,
16,
17,
18,
19,

R=C8H17 (M-P,8,8)
R=C10H21 (M-P,10,10)
R=C12H25 (M-P,12,12)
R=C14H29 (M-P,14,14)
R=C16H33 (M-P,16,16)
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4.2 Results & Discussion
Effective concentration and therapeutic index
The percentage of hemolysis for compounds with MIC (minimum inhibitory concentration) values ranging
from 1-250 µM was determined (Fig. 17). The concentration of amphiphile that resulted in 50% hemolysis
(EC50) was used to calculate the therapeutic index (TI). The TI of each compound was calculated for
representative Gram-positive and Gram-negative pathogens (S. aureus and E. coli) by dividing the EC50 by
the MIC (Table 8). Several amphiphiles have therapeutic indices greater than two, meaning the
concentration considered to be safe with red blood cells was higher than the MIC (Table 9)

Notably, compound 15 (M-P,10,10) has TI values of 65 and 8.1 against S. aureus and E. coli, respectively
(Table 9). The selectivity of MTable 8. Comparison of minimum inhibitory concentration (MIC),
hemolytic effective concentration (EC), and therapeutic indices of
amphiphiles from this study and tobramycin. Bold values indicate
compounds with therapeutic indices > 2. ND= Not determined. G(+) =
Gram-positive.; G(-) = Gram-negative; EC50 = Effective concentration
that resulted in 50% hemolysis.
!!

!!

!!

!!

MIC (µM)
S. aureus
E. coli
(G+)
(G-)

!!

comparable to the reported
therapeutic indices of cationic
!!

Therapeutic Index
S. aureus
E. coli
(G+)
(G-)

amphiphiles from other studies,
ranging from 10-171 (Table 8,

Compound

EC50 (µM)

4 (M-1,1,14)

130

63

250

2

0.5

5 (M-1,1,16)

9.3

31

31

0.3

0.3

6 (M-1,1,18)

4.3

16

16

0.27

0.27

P,10,10) for S. aureus is also

7 (M-1,1,20)

4.3

16

31

0.27

0.14

comparable to the in vitro TI of

11 (M-1,10,10)

130

16

125

8.1

1

12 (M-1,12,12)

8.6

2

4

4.3

2.2

13 (M-1,14,14)

3.8

8

8

0.475

0.5

14 (M-1,16,16)

4.6

16

63

0.2875

0.07

15 (M-P,10,10)

130

2

16

65

8.1

16 (M-P,12,12)

9.3

2

4

4.7

2.3

17 (M-P,14,14)

4.3

4

16

1.1

0.26

18 (M-P,16,16)

4.3

!!

!!
!!
Tobramycin

	
  

!!

P,10,10 for S. aureus and E. coli is

!!

32
!!

125
!!

0.13
!!

MIC (µM) !!
P. aeruginosa
(G-)
EC50 (µM)
Therapeutic Index
140

2

70

tobramycin for the Gram-negative
pathogen P. aeruginosa (TI = 70).
In comparison to other bacteria, P.
aeruginosa is intrinsically resistant
to many antibiotics, typically

0.03
!!

!!

Table 9). 37,49 The TI of 15 (M-

!!

requiring a larger concentration of
antibiotic to be killed. Still, the
large TI of M-P,10,10 for S. aureus
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suggests this compound has potential for treatment of S. aureus infection or disinfection of contaminated
surfaces.

Although compound 15 (M-P,10,10) is not the most effective amphiphile against the Gram-negative E.
coli, it has the highest TI values for E. coli and S. aureus (Table 8). When assessing effectiveness and
safety, compound 15 (M-P,10,10) is a candidate for further investigation in safety studies with epithelial
cell lines. Worth noting, several compounds have therapeutic indices ranging from 2-8, including 10 (M1,10,10), 11 (M-1,12,12) and 16 (M-P,12,12), and will also be investigated in additional toxicity studies
(Table 8).

a

140"

b

M-1,1 series

120"

120

Percent hemolysis

100"

100
M"1,1,14'

80"

M"1,1,16'

60"

M"1,1,18'

40"

M"1,1,20'

M"1,10,10'

80

M"1,14,14'

60

M"1,16,16'

40

M"1,12,12'

20

20"

0

0"
2

4

c

140

Percent hemolysis

M-1 series

140

8

16

31

2

63 125 250

M-P series

140

120

120

100

100
M"P,10,10'

80

M"P,14,14'

60

M"P,16,16'

40

M"P,12,12'

20

4

8

16

31

63 125 250

Tobramycin

d

80
60
40
20

0

0
2

4

8 16 31 63 125 250
Concentration (µM)

2

4

8

16 31 63 125 250
Concentration (µM)

Figure 17. Dose-response curves for (a) M-1,1 (b) M-1 (c) M-P and (d) Tobramycin. Hemolysis
assays were repeated three times for amphiphiles and twice for tobramycin. The average percent
hemolysis is represented for each amphiphile. Error bars indicate the standard deviation of the
average percentage.
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Table 9: Comparison of minimum inhibitory concentration (MIC), hemolytic effective concentration (EC), and
therapeutic indices of amphiphiles from this study and two other studies. Representative amphiphiles had the highest
therapeutic index within a particular series. MIC values represent MICs for S. aureus and E. coli for this work and the
double-headed compound and Mycobacterium avium for the anionic triple-headed compound. (G+) = Gram-positive;
(G-) = Gram-negative.
MIC (µM)
Representative Compound
[tail length(s)]

Hemolysis

Therapeutic index

(G+)

(G-)

EC (µM)

Method

(G+)

(G-)

Reference

2

16

130

EC50, sheep
blod

65

8.1

This work

NA

[49]
Falkinham,
et al.
Tuberculosis
2012, 92,
173-181.

10

[37] Hoque,
et al.
Langmuir
2012, 28,
12225-12234

Cationic Triple-headed,
double tailed [10,10]

3

NA

480

EC10, sheep
blood

171

Anionic Triple-headed,
double tailed [10,10]

13

10

128

EC50, human
blood

13

Double-headed, double
tailed [12,12], n=6

Structure-hemolytic activity trends
Both length and number of tail(s) has an effect on hemolysis. Generally, the hemolytic activity of a
compound increases as hydrophobicitiy increases. All three series of amphiphiles follow the trend that
hemocytoxicity increases with increasing tail length, which is consistent with other studies (Table 8, Fig.
17).

37

When comparing the effect of number of tails on cytotoxicity overall, the single-tailed series (M-1,1)

has higher EC50 values than the double-tailed series (M-1 and M-P) (Table 8). However, when comparing
compounds with equal total number of carbons in the tail(s) – 7 (M-1,1,20), 10 (M-1,10,10), and 15 (MP,10,10) – the double tailed compounds 10 and 15 had higher EC50 and TI values than the single tailed 7

	
  

	
  

51	
  

(M-1,1,20) (Table 8). The composition of the third head group did not significantly affect hemolytic
activity (M-P and M-1 series) (Table 8).

4.3 Conclusions
The cytotoxicity of three novel series of amphiphiles was determined with sheep red blood cells, and the
effect of amphiphile structure on hemolytic activity was investigated. Increasing hydrophobicity of
compounds contributed to increases in cytotoxicity. Worth noting, compound 15 (M-P,10,10) had high
selectivity for S. aureus (TI=65) and E. coli (TI=8.1). The TI of 15 (M-P,10,10) for S. aureus is indirectly
comparable to the TI of tobramycin for Gram-negative P. aeruginosa (TI = 70). Compound 15 and several
other compounds with TI values >2 may have promise as nontoxic drug candidates and will be investigated
in additional cytotoxicity studies.

4.4 Methods	
  
Hemolysis assay
For the hemolysis assay, defibrinated sheep blood (Fisher Scientific) and buffers were warmed to 37º C.
Red blood cells were suspended in Ringer’s solution (7.2 g/L NaCl; 0.37 g/L KCl; 0.17 g/L CaCl2) and
centrifuged at 1500 RCF. Supernatant containing lysed cells and plasma was disposed of, and pelleted red
blood cells were resuspended in PBS. Wash steps were repeated until the supernatant was clear. Red blood
cells resuspended in PBS were counted using a hemacytometer and diluted to 2 x 108 cells/ml in PBS. Five
hundred microliters of the red blood cells (108 cells/mL) were then incubated with 500 µL of amphiphile
(diluted 1:2 with PBS) at concentrations ranging from 2-250 µM. Water was used as a positive control for
hemolysis and PBS was used as a negative control. The samples were incubated for 20 min at 37º C. The
samples were then centrifuged at 1500 RCF for 20 min. Triplicates of 100 µL supernatant were pipetted
into a 96-well plate, and the OD450 values were recorded using a microtiter plate reader. The averages of
each triplicate were calculated and the percent hemolysis was determined using the formula:
% hemolysis = OD450 Compound – OD450 PBS X 100
OD450 Water – OD450 PBS
where OD450 Compound is the OD of the sample incubated with an amphiphile; OD450 PBS is the negative
control to account for spontaneous lysis; and OD450 Water is the positive control for hemolysis.
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Hemolysis assays were repeated three times for each amphiphile and twice for tobramycin. The average
percentage of hemolysis and standard deviation were calculated.

Statistical Analysis
In order to determine the EC50, the Gauss-Newton method for nonlinear regression was used to estimate the
parameters for the following drug response model:

yi= β0 –

β0
1+(xi/β2)β1

+ εi

where xi is the dosage level at level i and y is the response variable as a percentage of maximum possible
responsiveness. β0 is the expected response at dose saturation, β2 is the concentration that produces a halfmaxima response, and β1 determines the slope. Nonlinear regression analyses were performed using SAS
version 9.3. SAS code for the Gauss-Newton method is included in the appendix.
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Chapter 5: Conclusions
Synthesis and colloidal properties
Three novel series of triple-headed amphiphiles were synthesized, and the effect of tail length (8-22
carbons), number of tails (1-2), and head group composition (trimethyalammonium or pyridinium) on
colloidal and antibacterial properties was investigated. Overall, the critical aggregation concentration
(CAC) values are higher for single tailed amphiphiles, indicating the single tailed amphiphiles are more
soluble in solution. The log(CAC) decreases linearly with increasing tail length for all three series with a
moderate dependence on tail length for single tailed amphiphiles (M-1,1 series) (slope = -0.16) and cogent
dependence on tail length for the double tailed amphiphiles (M-P and M-1 series) (slope = -0.3). The CAC
was not affected by modification of the third head group from trimethylammonium (M-1 series) to
pyridinium (M-P series) for the double tailed compounds.

Antibacterial activity
The minimum inhibitory concentration (MIC) of compounds were determined for four Gram-positive and
two Gram-negative organisms. The antibacterial activity of all three series is affected by tail length, as each
series has one compound with an optimal tail length. For the double tailed series (M-P and M-1),
compounds with two tails each consisting of 12 carbons are the most effective, with MICs ranging from 216 µM. The single tailed series (M-1,1) has an optimal tail length of 18 carbons (MICs=2-125 µM). These
optimal tail lengths are consistent with amphiphiles from other studies, where double-tailed compounds
typically have an optimal tail length between 12-16 carbons and tricephalic compounds have optimal tail
lengths around 20 carbons. 35,39,49,54

In addition to tail length, the number of hydrophobic tails plays a role in antibacterial activity. The most
effective compounds from the double tailed series have lower MIC values than the most effective single
tailed amphiphiles. However, when comparing single tailed and double tailed compounds with an
equivalent number of total carbons in the tail(s), a trend is not as apparent. For example, when comparing
compounds with 16 carbons total in the tail(s), the single tailed M-1,1,16 was much more effective than
double tailed M-P,8,8. However, amphiphiles with 20 carbons in the tail(s) (M-1,1,20 and M-1,10,10) have
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approximately equivalent MICs. Modification of the third head group from trimethylammonium to
pyridinium did not impact antibacterial activity, with approximately equivalent MIC values for the M-P and
M-1 series.

These amphiphiles have broad-spectrum efficacy and have potential for the treatment of bacterial infection,
sterilization of contaminated equipment, and the prevention of bacterial colonization on surfaces. The
association of antibiotic-resistant pathogens with hospital-acquired infection demonstrates the need for new
effective antibacterial drugs. The efficacy of antibacterial amphiphiles against antibiotic resistant
pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA), will be investigated by our
research group. Compounds that inhibit MRSA and other antibiotic resistant pathogens could prove
invaluable in healthcare facilities.
In order to determine if combinations of amphiphile could enhance antibacterial activity, the interactions
between binary combinations of M-1; M-1,1; and/or M-P amphiphiles were studied using the microbroth
checkerboard method. Three synergistic binary combinations were identified, all of which consist of MP,12,12 combined with another double tailed amphiphile. These synergistic combinations decreased the
MIC of M-P,12,12 to less than 1 µM with S. aureus.
Other research groups have reported amphiphiles that act synergistically in vitro with other antibacterial
agents, including antibiotics, ethanol and other amphiphiles. 38,62,132 In addition, one hospital study
demonstrated that combination of amphiphiles with triclosan in antibacterial hand soap decreased the
transmission of bacteria. 85Additional benefits of synergistic combinations of antibacterial agents include
lower mortality rates when treating bacterial infection and decreased risk of the development of resistance.
15,76-80,82

Synergistic combinations containing M-P,12,12 are strong candidates for further investigation

concerning efficacy against MRSA and other pathogens. In addition, the interactions of M-P,12,12 and
other antibacterial amphiphiles with antibiotics will be investigated by our research group. The use of
synergistic combinations of amphiphiles and antibacterial drugs in a clinical setting could prove beneficial
by increasing the spectrum of antibacterial agents and impeding the development of resistance.
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Cytotoxicity
Compounds were tested with red blood cells to identify compounds that may be hemocompatible. The
safety of amphiphiles was assessed by determining the therapeutic index (TI) – defined as the EC50 divided
by the MIC. A large TI is indicative of compounds that are presumably safer. M-P,10,10 has the largest TI
for in vitro treatment of S. aureus (TI=65), which was comparable to the TI of tobramycin for the Gramnegative pathogen P. aeruginosa (TI=70). In addition, several other compounds have TI values ranging
from 2-8 (M-1,10,10; M-1,12,12; and M-P,12,12), suggesting these compounds may be hemocompitable. In
order to continue the investigation of the safety of these compounds, toxicity tests with epithelial cell lines
are in progress.

Future studies and potential applications
Several compounds with broad-spectrum antibacterial activity and large therapeutic indices were identified
(M-P,10,10; M-P,12,12; M-1,12,12). The safety of these compounds will continue to be investigated in
different models, including epithelial cell lines. Because of presence of antibiotic resistant organisms in
hospitals, these compounds will also be tested individually and in combination with methicillin-resistant S.
aureus (MRSA). In addition, activity against other pathogens including the influenza virus, fungi, and
spore-forming bacteria will be explored by our research group.

Several amphiphiles from this study have broad-spectrum activity against multiple pathogens and are
nontoxic to red blood cells at concentrations greater than their MIC values. These compounds could play a
role in combatting antibiotic resistance, especially as the development of novel antibiotics continues to
decrease. The extensive antibacterial activity of these amphiphiles allows for a range of potential
applications to be considered, including treatment of bacterial infection and sterilization of contaminated
hospital equipment.
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Appendix
SAS Code for Gauss-Newton Nonlinear regression:
DATA m114;
INPUT x y;
datalines;
2
0.316
2
-0.23
2
0.943
4
.417
4
0.230
4
1.11
8
0.189
8
0.115
8
.632
16
1.04
16
0
16
0.790
31.25 0.283
31.25 0.574
31.25 1.42
62.5
8.11
62.5
6.54
62.5
6.793
125
65.6
125
22.6
125
56.5
250
102
250
98.9
250
92.6
;
run;
PROC GPLOT DATA = m114;
PLOT y*x;
run;
PROC NLIN DATA = m114 METHOD=GAUSS HOUGAARD;
PARAMETERS
a=0 to 100
b=2 to 250
c=1;
model y = a-(a/(1 +(x/b)** c));
OUTPUT out=nlinout predicted=pred r=res;
run;
symbol1 v=circle l=32 c = black;
PROC GPLOT DATA=nlinout;
PLOT res*pred / VREF=0;
run;
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